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Protein Arginine Methyltransferase 6 (PRMT6) is the histone tail writer that 
methylates the H3R2 (arginine 2 of histone H3) residue, which counteracts the 
activating H3K4me3 mark. PRMT6 has been shown to behave both as 
transcriptional co-repressor (i.e. trhrombospondin-1, p21, p53), and co-activator 
(nuclear receptors). The co-repressor function of PRMT6 is likely the result of 
H3K4me3 antagonism, while the mechanism by which PRMT6 exerts its co-
activator function has yet to be elucidated. PRMT6 is over-expressed in several 
types of tumors including small cell lung cancer, lymphoma, cervical cancer, bladder 
cancer, oligodendroglioma, breast cancer, and osteosarcoma, suggesting an 
oncogenic role for this enzyme. Importantly, we have found a positive correlation 
between PRMT6 over-expression and H3R2me2a elevation in small cell-lung 
cancer tissue arrays.  
The aim of this project was to study the consequence of PRMT6 over-
expression and the effects of elevated histone arginine methylation at the 
organismal level in inducible PRMT6 gain-of-function mouse models. To this 
purpose, I generated two different systems. One mouse model is based on an ER*-
Flag-PRMT6 fusion (under a beta-actin promoter), while the other model is based 
on a Cre-inducible system, generated by cloning a floxed transcriptional Stop 
cassette upstream a Flag-PRMT6 (under a beta-actin promoter). Upon PRMT6 
induction, both mouse models show elevated asymmetric dimethylation of H3R2 
compared to wild type mice, demonstrating for the first time that PRMT6 methylates 
this residue in vivo. The ER*-PRMT6 mice die upon stabilization of the chimera and 
serum analyses have revealed elevation of Interleukin 6 (IL-6) levels, a key 
interleukin regulated by the transcription factor NF-B. This finding has led us to the 
discovery that PRMT6 functions as a co-activator for NF-B. I have found that 
PRMT6 is in the NF-B complex, and that its overexpression enhances NF-B 
transcriptional activity in luciferase assays and quantitative Real-Time PCR 
experiments. The activity of PRMT6 is clearly necessary for the coactivator function. 
ChIP analysis demonstrated that PRMT6 was recruited to the IL-6 promoter upon 
TNF-alpha stimulation. Moreover overexpression of PRMT6 caused RelA shuttling 
into the nucleus in our system, which could justify, at least in part, the mechanism 
underlying the coactivator function. I have also found that PRMT6 can deposit the 
H4R3me2a activating mark in vivo, which could explain the co-activator role of this 
arginine methyltransferase.  
The Cre-inducible PRMT6 transgenic mice have been crossed with a mouse 
line expressing a Cre recombinase under a Keratin 5 (K5) promoter, as well as with 
a MMTV-Cre mouse line. I have conducted carcinogenesis studies with these mice. 
The K5-Cre crossed mice have been subjected to skin carcinogenesis study using 
the DMBA/TPA system and to a p53+/- genetic cross. The MMTV-cre crossed mice 
have been subjected to ageing studies. I have also performed RNA-seq 
experiments on primary mammary epithelial cells from the MMTV-Cre crossed mice. 
In conclusion, this work identifies PRMT6 as a novel regulator of the 
inflammatory process, indeed we found that it cooperates with the transcription 
factor NF-B in activating early response inflammatory genes such as IL-6 and TNF-
alpha.  
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 Chapter 1 
Introduction 
 
1.1 Arginine methylation  
Arginine methylation is an important post-translational modification catalyzed by the 
protein arginine N-methyltransferase (PRMT) family of enzymes, composed by nine 
members. Arginine methylatilation is involved in a many cellular processes, like 
transcription, RNA metabolism, and DNA damage repair (1). Arginine residues can 
be methylated in three different modes on the guanidino group: monomethylated 
(MMA), symmetrically dimethylated (sDMA) and asymmetrically dimethylated 
(aDMA), and each of these methylated states can result in different biological 
outcomes (Figure 1). There are nine PRMTs – type I and type II enzymes (PRMT1, 
2, 3, 4, 6 and 8) catalyze the formation of a MMA, type I PRMTs further catalyze 
aDMA formation, while type II PRMTs (PRMT5) catalyze the formation of sDMA. 
PRMT7 is a type III enzyme that predominantly catalyzes MMA, and the PRMT9 has 
yet to be characterized (Figure 2). Arginine methylation constitutes a signal to recall 
readers of the histone code. This recognition event is fundamental in order for 
specific biological outcomes to happen. For example, methylation of SmB by 
PRMT5 is required for an interaction with the Tudor domains of SMN and TDRD3 
(2), methylation of CA150 by CARM1 also provides a docking site for SMN (3), and 
H3R17 methylation by CARM1 promotes TDRD3 binding (4). Thus, motifs harboring 
either aDMA or sDMA residues bind a subset of Tudor domain-containing proteins. 
An aromatic “cage” in the Tudor domain forms the methyl-binding pocket (5). 
Arginine methylation can also block protein-protein interactions. For example, the 
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methylation of arginine residues in the vicinity of proline-rich motif can block the 
binding to Src homology 3 (SH3) domains (6). Another example of arginine 
methylation blocking a protein-protein interaction is the CARM1-modified-GRIP1 
binding domain of p300 (5). Finally, the methylation of histone H3R2 (by PRMT6) 
antagonizes the binding of effector proteins to the N-terminal tail of H3, thus serving 
as a repressive mark that counteracts the activa H3K4me3 mark (7-9). 
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Figure 1. Types of Methylation on Arginine Residues.   
From Bedford and Clarke, 2009 (1).  
Copyright License number 3324800889013 (Molecular Cell). 
 4 
 
 
 
 Figure 2. The Protein Arginine Methyltransferase Family. The mammalian PRMT family 
currently contains nine highly related members; all harbor signature motifs I, post-I, II, and III 
and the conserved THW loop (in black bars). Protein domains that might assist in substrate 
recognition are marked in gray boxes.  
From Bedford and Clarke, 2009 (1).  
Copyright License number 3324800889013 (Molecular Cell). 
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1.2 PRMT6 
PRMT6 is an enzyme with auto-methylation capabilities that localized strongly in the 
cell nucleus (10). Substrates for this PRMT include the nuclear scaffold protein 
HMGA1a/b (11,12), DNA polymerase beta, and the HIV Tat protein (13,14). PRMT6 
has also shown to impact the histone code, indeed it is the primary enzyme 
responsible for H3R2 methylation in mammalian cells (7-9). PRMT6 can strongly 
methylate H3K4me1 and H3K4me2 peptides, and weakly methylate a H3K4me3 
peptide (7). However, prior methylation of the H3R2 site prevents the MLL1 complex 
from methylating H3K4 (9). H3K4 methylation is found in promoters of active genes 
and recalls chromatin-remodeling enzymes that open chromatin for transcription. 
The effector molecules that recognize H3K4me3 possess methyl-specific binding 
domains, like PHD, Chromo and Tudor domains. H3R2 methylation blocks the 
capability of many specific domains to bind to H3K4me3 in in vitro assays (7). 
Therefore PRMT6, by generating the H3R2me2a mark, functions as a 
transcriptional repressor because this mark impedes recruitment of remodelers to 
the H3K4me3 mark (Figure 3). In a massive qChIP study to identify the histone 
marks that are present on chromatin prior to Myc binding, it was found that 
H3R2me2a (the PRMT6 mark) is associated with the repressive H3K27me3 mark 
(deposited by EZH2) and low-affinity Myc binding site (15). Related studies by the 
same group found a negative correlation between H3R2me2a and H3K4me3, and a 
negative correlation between H3R2me2a promoter methylation and transcription (8). 
This finding supports the proposed role of PRMT6 in transcriptional repression and 
implicated this PRMT in the regulation of Myc recruitment and binding to chromatin. 
In yeast, the H3R2me2a mark has also been associated with transcriptional 
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repression, although the yeast enzyme that deposits this mark has not yet been 
identified (16,17). The tumor suppressors p21, p27 and p53 have been recently 
reported to be directly repressed by PRMT6 through deposition of the repressive 
H3R2me2a mark in their promoters (18-21).  PRMT6 also deposits the 
H2AR29me2a mark, which is enriched at the promoters of genes that are 
transcriptionally repressed by PRMT6 (22). 
The assumption that PRMT6 is a transcriptional repressor has recently been 
challenged by finding it functioning as SHR coactivator: Its mode of action is similar 
to that of PRMT1 and CARM1, indeed it functions as a secondary coactivator to 
p160/SRC proteins. PRMT6 binds to SRC-1, and acts synergistically with SRC-1 to 
coactivate ERα (23), but the mechanism for this coactivator function is yet to be 
elucidated. PRMT6 also methylates the N-terminal tails of histones H4 and H2A 
(their first 5 residues are the same) at R3 in in vitro reactions (9); however the 
methylation of these sites is yet to be shown in vivo. The H4R3me2a is known to be 
associated with actively transcribed gene promoters, and it is deposited primarily by 
PRMT1 in vivo (24). In the coactivation context, methylation of H4R3 and/or other 
active sites may be important. Indeed, PRMT6 has recently been reported to 
methylate H3R42 and that this non-tail histone methylation event positively affects 
transcription, likely by disrupting the histone-DNA interaction and making the 
nucleosome slidable (25). 
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Figure 3. The site of PRMT6-mediated methylation on the H3 histone tail is noted. The well-
characterized CARM1 methylation sites, which are associated with transcriptional activation, 
are also indicated. H3R2 methylation structurally impedes the binding of H3K4me3 recognition 
domains and also prevents H3K4 methylation by the MLL1 complex. H3R2 methylation 
antagonizes the docking of a number of H3K4me3 effector proteins. PRMT6 thus functions as 
a general transcriptional repressor by blocking the activator functions H3K4me3. From 
Bedford and Clarke, 2009 (1).  
Copyright License number 3324800889013 (Molecular Cell). 
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1.3 PRMTs and Nuclear Factor Kappa B (NF-B) 
Nuclear factor Kappa B (NF-B) is an inducible transcriptional factor that plays a 
pivotal role in immune system regulation, cell survival, differentiation and 
proliferation (26). Dis-regulation of NF-B has been associated with numerous 
diseases, including malignancies in which it is intrinsically activated, resulting in 
tumor survival by enhancing transcription of proliferative and anti-apoptotic genes 
(27). Five NF-B family members in mammals have been described: RelA/p65, 
RelB, c-Rel, p50 (NF-B 1), and p52 (NF-B 2). The N-termini of NF-B factors 
harbor a conserved region of 300 amino-acids, called Rel homology domain (RHD). 
Of the five members described, only p65, c-Rel, and RelB have C-terminal 
transactivation domains (TADs), which function to activate transcription (28). NF-B 
proteins bind either as homodimers or heterodimers to the target DNA - 
RelA(p65)/p50 dimer is the most abundant and well studied NF-B form. NF-B 
dimers are retained in the cytoplasm in normal conditions by association with the 
inhibitory IB proteins. Extracellular stimuli such as cytokines (i.e. tumor necrosis 
factor alpha (TNF-alpha)), bacterial lipopolysaccharide (LPS), and others activate 
phosphorylation cascades that result in phosphorylation, ubiquitination, and 
proteasomal degradation of IB proteins, with consequent translocation of NF-B 
dimer into the nucleus and transcription of target genes (29,30). Intracellular 
responses to DNA damage and reactive oxygen species can also activate NF-B 
(26). NF-B-dependent gene transcription requires multiple co-activators that 
function by bridging it to the basal transcription machinery and altering chromatin 
structure (31). The co-activators histone acethyl-tansferases p300 and its homolog, 
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the CREB-1-Binding Protein (CBP), are known to impact NF-B-dependent gene 
expression and have been shown to interact directly with RelA. Moreover NF-B-
dependent gene expression involves another class of transcriptional coactivators, 
such as steroid receptor-coactivator-1 (SRC-1), which interacts with the p50 subunit 
of NF-B to potentiate transactivation (32). In Figure 4 is shown the complex 
(Enhanceosome) that forms at IL-6 promoter one of the NF-B target genes (33). 
Members of the protein arginine methyltransferase family (PRMTs), namely PRMT1 
and PRMT4/CARM1, well known as steroid hormone receptor (SHR) coactivators 
(34,35), have also been shown to cooperate in NF-B-dependent gene activation. 
CARM1 has been shown to function as promoter-specific coactivator for NF-B in 
concert with p300/CBP and SRC-2/TIF2/GRIP1 through deposition of the 
H3R17me2a active mark at NF-B-regulated promoters (36,37). PRMT1 has been 
reported to coactivate NF-B-dependent gene expression synergistically with 
CARM1 and PC1/poly(ADP-ribose) polymerase 1 (PARP1) (38).  
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Figure 4. Overview of the phosphorylation pathways leading to activation of the IL-6 enhanceosome. The 
expression of IL-6 needs to be very strictly regulated and the IL-6 gene promoter contains a plethora of 
sequence elements, which can be triggered via different activation schemes. Induction of IL-6 by the 
inflammatory cytokine TNF is exclusively mediated by the stress-responsive transcription factor NF-kB. 
However, other DNA-bound transcription factors also contribute to the general level of expression and help to 
establish a multi-protein complex, a so-called ‘enhanceosome’, at the promoter DNA. Herein, NF-kB serves as 
the ultimate trigger to turn this enhanceosome into a fully transcriptionally competent complex, which is capable 
of gene induction. (Ac, acetyl; AP-1, activator protein-1; BTM, basal transcription machinery; C/EBP, CCAAT 
enhancer-binding protein; CREB, cAMP-responsive element binding protein; p/CAF, p300/CBP-associated 
factor; Pol, polymerase; SRC, steroid receptor activator. 
Suorce: (33). Copyright License number 3324800111184 (the EMBO Journal). 
 
 
 11 
 
1.4 PRMTs, PRMT6 and Cancer  
PRMTs have been shown to impact numerous cellular processes, including 
proliferation, transformation and the anti-apoptotic pathway, therefore they may play 
an important role in tumorigenesis (39). PRMT1 mRNA levels have been reported to 
be higher in breast cancer cell lines than in controls (40). In addition, PRMT1 plays 
a role in the transforming abilities of the MLL-EEN gene fusion product (41). CARM1 
levels are elevated in castration-resistant prostate cancer, as well as in aggressive 
breast tumors (42,43). Importantly, CARM1 methylates AIB1, thereby regulating its 
activity and stability (44,45). CARM1 is recruited to ER regulated promoters by 
AIB1, and it is essential for estrogen-induced proliferation of the MCF-7 breast 
cancer cell line (46). Moreover, while this thesis was being written, a publication 
showed that CARM1 methylates the chromatin remodeling factor BAF155 to 
enhance tumor progression and metastasis (47). PRMT5 is recruited by SNAIL to 
actively repress E-cadherin expression (48). A hallmark of epithelial-mesenchymal 
transition (EMT) is the loss of E-cadherin expression, which plays an important role 
in tumor progression. PRMT5 overexpression promotes anchorage-independent cell 
growth (49), supporting the notion that PRMT5 might be an oncoprotein. Consistent 
with this idea, PRMT5 levels are elevated in gastric cancer (50) and in leukemia 
cells (51). Microarray analysis of PRMT6 knockdown cells revealed that 
thrombospondin-1 (TSP-1) is transcriptionally repressed by this PRMT (52). TSP-1 
is a potent natural inhibitor of angiogenesis, and reduction of its levels have been 
shown to promote tumor progression. The HOXA10 gene is strongly regulated 
(repressed) by PRMT6 activity (9). HOXA10 is a positive regulator of the p53 tumor 
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suppressor gene (53). Thus, increased PRMT6 levels will result in decreased 
HOXA10 levels and consequently attenuated p53 function. Moreover, as already 
mentioned, the tumor suppressors p21, p27 and p53 have been recently reported to 
be directly repressed by PRMT6 through deposition of the repressive H3R2me2a 
mark in their promoters (18-21). 
As already mentioned, PRMT6 generates the H3R2me2a mark, and the majority 
of H3K4me3 effector molecules are sensitive to H3R2me2a methylation (7). A key 
group of these H3K4me3 readers that are blocked from binding are the ING family 
of PHD domain-containing proteins. ING proteins are down-regulated in a broad 
variety of cancer types and are regarded as tumor suppressors (54). Elevated 
PRMT6 levels result in increased H3R2me2a methylation, which in turn will 
effectively incapacitate ING protein effector functions. A search of the Oncomine 
transcriptome database (www.oncomine.org) confirmed that indeed PRMT6 is over-
expressed in a number of tumors, including SCL, cervical cancer (Figure 5A), as 
well as acute lymphoblastic leukemia and others (data not shown). In addition, 
PRMT6 expression levels correlate with poor prognosis in oligodendroglioma 
patients (Figure 5B). To confirm this observation at the protein level, we obtained 
small cell lung carcinoma tissue microarrays from Folio Biosciences, which had 33 
carcinomas and 5 normal samples arrayed. These arrays were probed for both 
PRMT6 and for the mark that it deposits, H3R2me2a (Figure 5C). In the normal 
lung tissue, PRMT6 levels were mostly below the level of detection (although there 
was strong non-specific cytoplasmic staining in a subpopulation of cells, apparently 
of secretory material). All tumors had nuclear PRMT6 staining not seen in normal 
bronchial epithelium. The average % positive nuclei was 12.6% (range, 2.8-36.3%) 
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for PRMT6. In control bronchial epithelium, 5.9% cells had nuclear staining for 
H3R2me2a. Ninety-four percent (31/33) of tumors analyzed had higher proportions 
of H3R2me2a-positive nuclei than control tissue. On average, the percentage of 
positive nuclei in tumor cells (mean, 35.5%; range, 0.6-82.6%) was six-fold the 
percentage in control tissue and, overall, the H3R2me2a staining intensity was 
greater in tumor nuclei compared to non-neoplastic cell nuclei. Nuclear staining for 
H3R2me2a and PRMT6 was evaluated on slides scanned by an Aperio ScanScope 
using ImageMate software. An average of 14,000 tumor cells per sample were 
evaluated. Control tissue was bronchial epithelium from adjacent normal tissue, 
where small cell carcinomas of the lung are believed to arise. Altogether, 2,600 
control cells were evaluated.  
The H3R2me2a mark is deposited by PRMT6. Thus, tumor samples that 
overexpress PRMT6 should also display elevated levels of H3R2me2a. To establish 
if there is such a positive correlation between PRMT6 and H3R2me2a levels, paired 
analyses were obtained for 33 tumor samples and results were expressed as 
percentage immunopositive nuclei. Linear regression analysis was performed to 
determine if there was a relationship between PRMT6 and H3R2me2a staining 
(Figure 5D). A least squares rho value of 0.806 was obtained, with an F-test value 
of 9.2994. This indicates that PRMT6 values can explain approximately 80% of the 
variance in H3R2me2a values. An F value of greater than 4 is considered 
statistically significant. Thus, there is a positive correlation between PRMT6 and 
H3R2me2a staining. 
A detailed analysis of PRMT6 (and PRMT1) deregulated expression in different 
human cancers was performed. This study reported that PRMT6 is overexpressed 
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in a number of human cancers, including bladder, small cell lung carcinomas, 
lymphomas, breast cancer, and cervical cancer (55) (Figure 5E). Recently, PRMT6 
has also been found to be dramatically elevated in prostate carcinomas (56). 
 Thus, three separate lines of evidence support the fact that PRMT6 levels are 
significantly elevated in tumors: 1) Oncomine data, 2) tissue microarray analysis 
performed by us, and 3) a thorough analysis of PRMT6 levels in a large number of 
different tumors performed by the group of Hamamoto and a recent paper from the 
group of Jeronimo (55,56). Importantly, although there are numerous in vitro studies 
linking aberrant PRMT function to cancer, no mouse models have been developed 
to address this issue. 
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Figure 5. PRMT6 levels are elevated in tumors. (A) Analysis of the Oncomine database reveals 
that PRMT6 is significantly overexpressed in SCLC and cervical cancer. (B) PRMT6 expression 
levels correlate with poor prognosis in oligodendroglioma patients. (C) Tissue microarray analysis 
of PRMT6 and H3R2me2a in small cell lung carcinomas. Top two panels represent adjacent 
normal tissue. The other six panels represent three of the 33 carcinoma cores, stained for both 
PRMT6 and H3R2me2a. Pictures were taken by Donna Kusewitt. (D) Linear regression analysis 
was performed on the levels of PRMT6 and H3R2me2a in each sample; their expression levels 
strongly correlate. E, PRMT6 levels are elevated in a number of different tumors. The data is 
presented as a signal intensity ratio (Tumor/Normal). The data in (E) was published data adapted  
from Yoshimatsu et. al. 2011 (55). 
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1.5 DMBA/TPA skin carcinogenesis 
The two stage skin carcinogenesis system that employs the tumor initiator agent 
DMBA (7,12-dimethylbenz[a]anthracene) and the tumor promoter TPA (O-
tetradecanoyphorbol-13-acetate) has been largely employed to address of a number 
of questions about the fundamental biology of epithelial cancers (57). In this 
protocol, by administering a single dose of DMBA followed by repeated applications 
of TPA, mice develop initially primarily papillomas, which progress to Squamous 
Cell Carcinomas (SCCs) that are histologically very similar to human SCCs. In 
accordance with the cancer stem cells hypothesis for cancer development, the 
mechanism for tumor initiation in DMBA/TPA two-stage carcinogenesis protocols 
involves mutation in the critical target Ha-ras gene of stem cells. These cells are 
found in the bulge region of hair follicles or basal compartment of interfollicular 
epidermis in mice (57). The gene targets for initiation by chemicals in mouse skin 
resemble those found in other human epithelial cancers (e.g., lung, colon, and 
pancreatic cancers) (58). The tumor promoter TPA will affect gene expression, and 
stimulate epidermal cell proliferation. The progression of papillomas to SCC does 
not depend on the tumor promoter agent TPA, it rather occur stochastically following 
numerous gene expression changes (59,60). 
 
1.6 Innovation of this study 
The innovation of this project lies in the novel and sophisticated mouse models, 
which allow for the conditional and inducible modulation of PRMT6 activity to study 
the role of this PRMT in biological processes, such as cancer. There is evidence 
gleaned from in vitro experiments that PRMT6 functions as both a transcriptional 
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repressor and activator. In this study I sought to determine the biological relevance 
of these findings in an in vivo setting by investigating the transcriptional 
repressor/activator functions of PRMT6 in gain-of-function mouse models. This 
study is highly relevant due to the recent observations that PRMT6 is up-regulated 
in a number of tumors, including SCLC, lymphomas and cervical cancer (Figure 5). 
I have exploited novel mouse models to understand the role of PRMT6 in cancer 
development using state-of-the-art approaches. 
Epimutations, unlike genetic mutations, can be reversed by chemotherapeutic 
intervention, which makes epigenetic therapy conceptually extremely appealing. 
Drug therapies that target chromatin have been touted as the next emerging frontier 
for the treatment of cancer. Epigenetic drugs are currently being used in the clinic. 
Clearly, dramatic changes in epigenetic patterns and gene transcription are major 
signatures of cancer and PRMT6 may play a significant role in this reprogramming. 
The reversal of these aberrant patterns is emerging as a therapeutic strategy for the 
treatment of cancer.  
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Chapter 2 
Rationale, Hypothesis and Specific aims 
 
Rationale 
 PRMT6 is an arginine methyltransferase that was first identified and described by 
our group. PRMT6 has been reported to be the predominant enzyme to methylate 
the H3R2 (arginine 2 of histone H3) residue. The proximity of this arginine residue to 
the H3K4me3 activation mark raises the possibility of crosstalk between these two 
methylation events. PRMT6 likely functions as a transcriptional repressor in two 
ways: 1) by blocking the recruitment of transcriptional activators to the methylated 
H3K4 mark and 2) by preventing H3K4 methylation by MLL1. On the other hand, 
PRMT6 has recently been described as co-activator for nuclear receptors by the 
Dowhan’s group, although the mechanism for this coactivation was not described in 
the manuscript. A likely mechanism by which PRMT6 will function as a coactivator 
has recently come to light with the finding that it methylates a site in the core of 
histone H3, H3R42me2a and that this non-tail histone methylation event positively 
affects transcription, possibly by disrupting the histone-DNA interaction and making 
the nucleosome “slidable”. Moreover, PRMT6 has been shown to generate the 
active H4R3me2a mark in in vitro reactions, however this methylation event is yet to 
be shown in vivo. The ability of transcription factors and transcriptional regulators to 
function as both activators and repressors in a context dependent manner is not 
novel, and well-characterized examples include p53, myc, E2Fs, LSD1 and TRIM24. 
 Importantly, PRMT6 is over-expressed in several types of tumors including 
small cell lung cancer, lymphoma, cervical cancer, bladder cancer, 
 19 
oligodendroglioma, breast cancer, and osteosarcoma, suggesting an oncogenic role 
for this enzyme. Notably, we have found a positive correlation between PRMT6 
over-expression and H3R2me2a elevation in small cell-lung cancer tissue arrays. 
We would like to understand the consequence of altered PRMT6 expression at the 
organismal level.  
 
Hypothesis 
We hypothesized that PRMT6 is a major transcriptional regulator may contribute to 
cancer susceptibility. To explore the potential roles of PRMT6 in cancer 
development, we generated two PRMT6 gain-of-function mouse models. 
 
Specific Aim 1 - Generation and characterization of two types of PRMT6 gain-
of-function mouse models.  
Transgenic mouse lines over-expressing an ER*-Flag-PRMT6 chimera were 
generated. In order to produce these mice an ER*-Flag-PRMT6 sequence was 
cloned in the pCAGGS vector and the construct was employed for pronuclear 
injection, generating ER*-PRMT6 lines. As an alternative approach, we generated a 
transgenic mouse model based on a Cre-inducible system. For this second model, a 
transcriptional stop cassette was cloned upstream a Flag-PRMT6 in a pCAGGS 
vector and the construct was employed to produce transgenic mouse lines. These 
lines (called STOP-PRMT6) were crossed with mice expressing a Cre recombinase 
under a Keratin 5 promoter (K5-Cre mice) as well as with mice expressing a Cre 
recombinase under a MMTV promoter (MMTV-Cre mice). 
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Specific Aim 2 - To determine the impact of PRMT6 over-expression on skin 
carcinogenesis.  
A chemical skin carcinogenesis experiment was set-up with STOP-PRMT6 mice 
(crossed to the K5-Cre mouse line) employing the tumor initiator agent DMBA and 
the promoter TPA. A number of endpoints were compared between the control and 
experimental group, including tumor incidence, latency, multiplicity, and malignancy.  
 
Specific Aim 3 - To determine if increased PRMT6 activity cooperates with p53 
deficiency in tumor development.  
Mice heterozygous for p53 are prone to develop tumors by loss of the intact p53 
allele. The STOP-PRMT6/K5-Cre mice were crossed onto a p53+/- background to 
determine if increased PRMT6 activity cooperates with tumor development through 
epigenetic silencing of he p53 WT allele. 
 
Specific Aim 4 - To determine the impact of PRMT6 overexpression on the 
mammary gland.  
In order to investigate the impact of PRMT6 over-expression on the mammary gland 
we crossed the STOP-PRMT6 mice with a MMTV-Cre mouse line and characterized 
them.  The bigenic mice STOP-PRMT6/MMTV-Cre showed increased proliferation 
in the mammary gland epithelium, therefore we set-up ageing studies in order to 
explore the possibility of increased mammary tumorigenicity. We also performed a 
RNA-Seq experiment using primary mammary epithelial cells (organoids) isolated 
from the bigenic STOP-PRMT6/MMTV-Cre mice, along with 2 control groups  
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(STOP-PRMT6 and MMTV-Cre), in order to investigate the impact of PRMT6 
overexpression on the mammary transcriptome. 
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Chapter 3 
Materials and Methods 
 
Antibodies, cells and reagents 
HEK 293 and HeLa cells were purchased from ATCC and cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) containing pen strep, non-essential amino-acids 
and FBS 10%. Tamoxifen (cat. # T5648), OHT (cat. # H7904) and TNF-alpha (cat. # 
T6674) were purchased from Sigma.  Anti-RelA antibody for WB and IF was from 
Abcam (cat. # ab16502). Anti-hPRMT6 antibody was from Imgenex (cat. # IMG-
506). Anti-PRMT6 atibody (for mouse and human) was from Bethyl Laboratories 
(cat. # A300-929A). Anti-Flag antibody (cat. # F3165) and anti-Flag agarose (cat. # 
A2220) were obtained from Sigma. Anti-H3R2me2a antibody was from Millipore 
(cat. # 05-808). Anti-GFP antibody was from Life Technologies (cat. # A6455). Anti-
Lamin A/C antibody was from Santa Cruz (cat. # sc-20681). Anti- H4R3me2a was 
from Active Motif (cat. # 39705). Protein A/G Ultra Link resin was from Thermo 
Scientific (cat. # 53132).  DMBA was purchase from Sigma, TPA was from LC 
Laboratories (cat # P-1680). 
 
Transgene construction and mouse generation 
Estrogen receptor hormone-binding domain variant (ER*) that bind Tamox, but not 
estrogen, was a gift from Martin McMahon (61). ER* was generated by PCR (from 
the pBP3hbER* vector) and cloned into a pCAGGS construct containing flagged 
human PRMT6 cDNA. For the Cre-inducible construct, a Stop cassette was 
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amplified by PCR from the RAGE vector, previously described (62) and cloned into 
a pCAGGS construct containing flagged human PRMT6 cDNA. In both cases, an 
aliquot of the construct produced by Midi Prep using Qiagen kit (Qiagen Scientifics, 
Maryland) was linearized overnight using ScaI, then column purified using PCR 
purification kit from Qiagen (Qiagen Scientifics, Maryland). This transgene was 
injected into the male pronucleus of day 1–fertilized (FVB) embryos. Injected 
embryos were transferred into day 1–plugged pseudo-pregnant foster mice, and 
litters were screened for the presence of the transgene using Southern  analysis to 
identify heterozygous founders. Founder mice were backcrossed to establish lines 
of animals. 
 
Southern  genotyping 
Approximately 1000 bp of PRMT6 cDNA sequence was cloned out from a 
pCAGGS-Flag-PRMT6 construct to use as a template for probe generation by PCR 
using the primers Forward 5’-ATGGACTACAAGGACGACGATGACAA-3’ and 
Reverse 5’-GATAGGCAGCCTGCACCTGAGGAGTG-3’. The radiolabeled 
hybridization probe was prepared with 32P-dCTP using the Random Primer Labeling 
kit from Agilent Technologies (cat. # 300385), following manufacturer’s instructions. 
Genomic DNA was isolated from the tails of 3-week old mice and digested EcoRI 
enzyme. Digested DNA was run on 1% agarose gel overnight and transferred to a 
nitrocellulose membrane. The membrane was then cross-linked and incubated in 10 
mL Southern hybridization buffer containing SDS, the radioactive probe and salmon 
sperm DNA overnight at 42° C, then washed with SSC buffer (3.0 mol /L NaCl,  0.3 
mol /L sodium citrate) and exposed to film for 1–3 days at –80° C.  
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Administration of tamoxifen to mice  
To activate ER*-PRMT6 in adult transgenic mice by Tamox topical administration, 
Tamox was and applied topically to a shaved 
area of dorsal skin. As control, WT littermates treated with Tamox or transgenic 
littermates treated with ethanol, were included in these studies. For intraperitoneal 
 
 
Stable cell line generation 
HEK 293 cells were transfected with the pCAGGS-ER*-PRMT6 construct (10 g) 
along with an empty plasmid carrying neomycin resistance (1g). Selection of stable 
transfected cells was performed using neomycin (G418). 
 
Immuno-staining of mouse tissue and immuno-fluorescence HeLa cells 
Tissue samples were obtained from WT or transgenic mice, Tamox or vehicle 
treated. Tissues were fixed overnight in neutral buffered formalin (24 hrs), 
transferred to 70% ethanol, then embedded in paraffin and sectioned (5 μm). Slides 
were de-paraffinized with standard procedure. For immunohistochemistry (IHC), 
non-specific antibody binding was blocked by incubating slides with Biocare 
Blocking Reagent (cat# BS966M) for 10 minutes. Slides were drained and incubated 
with primary anti-Flag antibody for 30 minutes at room temperature, then washed 
with PBS and incubated with biotinylated rabbit-anti-mouse secondary antibody for 
15 minutes at room temperature.  After washing, slides were incubated with SA-
 25 
HRP (Biocare) for 30 minutes at room temperature, washed again and incubated 
with BioGenex DAB monitoring staining development. Slides were then washed, 
counterstained, dehydrated and mounted. For immunofluorescence (IF), after 
deparaffinization slides were blocked with 20% FBS 30 minutes, washed and 
incubated with primary antibody for 1hr, then secondary antibody Texas Red-
conjugated, followed by DAPI staining. In the case of HeLa cells, cells were grown 
on a coverslip to 70% confluency and transfected with GFP or GFP-PRMT6 for 24 
hrs. Cells were then rinsed with PBS and fixed with 4% paraformaldehyde for 15 
min at room temperature. Cells were washed with washing solution (0.1% NP-40 in 
PBS), blocked in 20% FBS, incubated with primary antibody anti-RelA (in washing 
solution) 1 hr at room temperature, washed 3 times incubated with secondary 
antibody Alexa Fluor 555-conjugated 30 minutes, and DAPI stained afterwards. 
 
Isolation of mouse embryonic fibroblasts  
Briefly, a 12.5-day plugged mouse was sacrificed following standard procedure. 
Intact embryos were collected and placed in 6-well plates containing 3 mL DMEM 
10% FBS and pen-strep. Embryos were mechanically disrupted passing them 
through a 5 mL syringe with a 18G needle 5 times, then plated in 10 cm dish 
containing 10 mL of media. Media was changed every day for 3 days. 
 
Western Blotting (WB)  and co-immunoprecipitation (co-IP) 
For total cell lysates, cultured cells (80% confluency) were scraped from a tissue 
culture dish, lysed in RIPA buffer containing protease inhibitor cocktail and 
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denatured by boiling. In the case of cell fractionation, the NE-PER kit from Thermo 
Scientific (cat. # 78835) was employed. For tissue lysates, tissues were harvested, 
snap frozen in liquid nitrogen, grounded using a mortar, transferred in RIPA buffer 
with protease inhibitors and sonicated 3 times using Fisher Scientific Sonicator 
Model 500 (25% power, 10 sec each cycle). Protein lysates (30-50 g) were 
resolved on SDS-PAGE gel. For the co-IPs cells were lysed in a mild co-IP buffer 
[50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM 
EGTA, 15 mM MgCl2] containing protease inhibitor cocktail and incubated with 
primary antibody anti-GFP or with anti-flag agarose O/N at 4 °C. In the case of anti-
GFP IP, lysates were incubated with protein A/G agarose the next day for 3hrs at 
4°C, then the agarose was washed in co-IP buffer 3 times, denatured by boiling and 
resolved on SDS-PAGE gel. In the case of anti-Flag agarose, we proceeded with 
washing the beads extensively, boiling and resolution on SDS-PAGE gel. The 
resolved proteins were transferred on PVDF membrane, incubated in 5% non-fat 
milk 30 min at RT, and subsequently incubated with specific primary antibody in 
non-fat milk overnight at 4 °C. The s were washed three times in PBS containing 
0.2% Tween-20 and incubated for 1 hr in peroxidase-conjugated IgG diluted 1/5000 
in non-fat milk at RT. s were washed and immune complexes detected with ECL. 
 
Acid extraction of histones 
For histone purification, cells were first fractionated using NE-PER kit from Thermo 
Scientific (cat. # 78835). After isolating the nuclear fractoion, 150 L of 0.8 M HCl 
was added to the chromatin pellet and sonication at 30% power using Fisher 
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Scientific Sonicator Model 500 (15 seconds) was performed. Samples were then 
centrifuged, and the supernatant neutralized adding Tris–HCl 1.5M, pH 8.5 (90 L) 
and loaded on SDS-PAGE gel for quantification by coomassie staining. 
 
Chromatin immunoprecipitation (ChIP) 
HeLa cells at 80% confluency were transfected with 10 μg of a FLAG-PRMT6 
vector. 24 h after transfection, cells were treated with TNF-alpha or PBS (vehicle). 
ChIP analysis was performed using the Millipore Magna ChIP assay kit protocol 
(cat# 17-610). For the immunoprecipitation, 2 μg of PRMT6 antibody was used for 
each condition and incubated overnight at 4°C. Quantitative Real time-PCR was 
performed with the Applied Biosystems 7900HT real-time PCR instrument using the 
iTaq Universal SYBR Green Supermix form Bio-Rad (cat. # 172-5121).  
The primer sequences were as follows:  
8000 upstream TSS:  
For. 5’- GCTCCTCCATCTGGTGTCAT-3’, Rev.5’-AAATTGGGGGTAGGGTTGTC-3’ 
IL-6 TSS:  
For. 5’-AATGTGGGATTTTCCCATGA -3’,Rev. 5’-AGTTCATAGCTGGGCTCCTG -3’ 
 
RNA isolation and quantitative real-time PCR 
RNA was isolated from 80% confluent cell plates using TRIzol Reagent (Invitrogen, 
Carlsbad, CA). cDNA was prepared from total RNA (1g) using the Superscript III 
First Strand Synthesis System for RT-PCR from Invitrogen (cat. # 18080-051) 
following the manufacturer's protocol. Quantitative Real time-PCR was performed 
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with the Applied Biosystems 7900HT real-time PCR instrument using the iTaq 
Universal SYBR Green Supermix form Bio-Rad (cat. # 172-5121) with primers for 
the indicated genes. Primers were designed across exons. 
The primer sequences were as follows:  
IL-6:  
For. 5’-ACTCACCTCTTCAGAACGAATTG-3’, Rev.5’-CCATCTTTGGAAGGTTCAGGTTG-3’ 
TNF-alpha:  
For. 5’-CCCCAGGGACCTCTCTCTAA-3’, Rev. 5’-TGAGGTACAGGCCCTCTGAT-
3’ 
MCP1/CCL2:  
For. 5’-TCTGTGCCTGCTGCTCATAG-3’, Rev. 5’-GCTTCTTTGGGACACTTGCT-3’ 
COX-2:  
For. 5’- TGAAACCCACTCCAAACACA-3’, Rev. 5’-GAGAAGGCTTCCCAGCTTTT-3’ 
IKB-alpha:  
For. 5’-AGACCTGGCCTTCCTCAACT-3’, Rev. 5’-TGCTCACAGGCAAGGTGTAG-
3’ 
GAPDH:  
For. 5’-AGCCACATCGCTCAGACAC-3’, Rev. 5’-GCCCAATACGACCAAATCC-3’ 
 
Luciferase reporter assay 
HEK 293 cells were cultured in 10% FBS supplemented DMEM in 24-well plates to 
70% confluency. For reporter gene assays, cells were co-transfected with 200 ng of 
the NF-B luciferase reporter plasmid, 25 ng Renilla control luciferase plasmid (pRL) 
and the indicated constructs (400 ng). The total plasmid content was balanced up to 
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625 ng with empty vectors when necessary. Cells were treated with TNF-alpha (10 
ng/mL) or PBS for 6 hrs before luciferase assay was done using Dual-Luciferase 
Reporter Gene Assay from Promega (Madison, WI). 
 
In-vitro binding assay 
Glutathione S-transferase (GST), GST-RelA (1-431), His-Tudor (UHRF1) and His-
PRMT6 were isolated from Escherichia coli BL21 cells following 5 h induction with 
IPTG. For GST fusion proteins, cells were harvested in PBS buffer plus protease 
inhibitors, sonicated and centrifuged to remove cell debris. GST-fusion proteins 
were purified by incubation with glutathione beads (Amersham Biosciences) 
overnight with rotation at 4°C. Beads were washed five times and bound proteins 
were eluted from the beads using freshly prepared reduced glutathione (33 mM).  
For His-tagged proteins, cells were lysed in appropriate lysis buffer (containing 1mM 
EDTA, 1mM EGTA, 5mM DTT and protease inhibitors), incubated with Ni-NTA 
agarose (Qiagen Scientifics, Maryland) overnight with rotation at 4°C, then eluted 
with elution buffer (containing 250mM imidazole).  10 ug of eluted GST fusion 
proteins and His-PRMT6 were incubated in co-IP buffer  [50 mM Tris-HCl (pH 7.5), 
150 mM NaCl, 0.1% Nonidet P-40, 5 mM EDTA, 5 mM EGTA, 15 mM MgCl2] 
overnight at 4°C. Complexes were then pulled down with glutathione beads for 2 hrs 
4°C, washed extensively in co-IP buffer and resolved on SDS-PAGE gel followed by 
WB analysis. 
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In vitro methylation assay 
In vitro methylation reactions were carried out in 30 μl of phosphate-buffered saline 
(pH = 7.4.), containing 0.5–1.0 μg of substrate, 3 μg of recombinant GST-PRMT6 
and 0.42 μm [3H]S-adenosyl-l-[methyl-3H]methionine (79 Ci/mmol from a 7.5 μm 
stock solution; PerkinElmer Life Sciences). The reaction was incubated at 30 °C for 
1 h and then subjected to fluorography by separation on SDS-PAGE, transferred to 
a PVDF membrane, treated with En3Hance™ (PerkinElmer Life Sciences), and 
exposed to film for 1–3 days at –80 °C.  
 
Isolation and culture of mouse primary keratinocytes 
Briefly, 1-2 day old pups were sacrificed according to standard procedures and skin 
was removed. Skins were placed on Trypsin-EDTA O/N 4 °C, then epidermis was 
carefully removed from the dermis, chopped with sterile blades and transferred in 
50-mL falcon tube containing Super media (with pen-strep, 10% FBS). Cells were 
then strained through a 70 m strainer after mixing 5 times with a 10 mL sterile 
pipette. Cells were left to adhere to a tissue culture dish for 3 hrs in Super media, 
then the media was replaced with keratinocyte basal media (Lonza, cat.# CC-3158) 
containing FBS 10%, pen-strep and additioned with components of the Lonza Kit 
KGM-2 SingleQuots (Cat.# CC-4152). 
 
Electroporation of primary MEFs 
About one million cells were trypsinized and washed extensively with PBS, then re-
suspended in 800 L of PBS and pulsed using Bio-Rad Gene Pulser Xcell 
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Voltage=500 Volts, Capacitance=600 farad and Resistance= ∞. Cells were 
immediately placed in complete media after electroporation. 
 
Mammary organoid isolation 
For mammary organoid isolation, we modified a protocol following Matthew J. 
Smalley. 8-12 week-old female mouse was euthanized and dipped a few seconds in 
70% EtOH. Using sterile material, the second, third and fourth pair of mammary 
glands were removed, rinsed quickly in sterile PBS and placed in L15/10%FCS in a 
tissue culture dish. Tissue was transferred into a clean, sterile tissue culture hood 
and minced manually with sterile razor blades, then transferred to a 50-mL conical 
polypropylene tube filled with 35 ml of working collagenase solution (prepared at the 
moment) and incubated at 37 °C with vigorous agitation (1.5 hrs).  Tissue was then 
centrifuged 5 min, 1400 rpm and the supernatant transferred in a clean tube and the 
centrifugation repeated. The two pellets were combined in 10mL L15/10%FCS 
medium, transferred in a new 15-cm tube and centrifuged again. The pellet from this 
centrifugation was re-suspended in 5 mL of red blood Lysis Buffer and left at room 
temperature 5 min, then centrifuged (5 min 1400 rpm). This step was repeated one 
more time. Pellet was then re-suspended in 10mL L15/10%FCS media and 
centrifuged again. To remove most of mammary fibroblasts, the pellet was re-
suspend in DMEM/10% FCS and transferred to a T-80 tissue culture flask and 
incubated in a regular cell incubator for 1.5 hr. Organoids were gently recollected, 
transferred in 15-mL tube, centrifuged 5 min at 1400 rpm and re-suspended in final 
media (DMEM/F12 (500 mL bottle) added with: 50 L FCS (10% final); 7L Pen-
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Strep; 500 L L-glatamine (4 M); 110 L (human or porcine) Insulin (10 mg/mL); 55 
L EGF (Epidermal Growth Factor) (100 g/mL)).  
 
Two-stage skin carcinogenesis 
Dorsal skin from 6-8 week old mice was shaved 2 days before initiation. Initiation 
was accomplished with a single application of 25 g DMBA and promotion by 
applying 5 g TPA/week twice a week for 23 weeks, staring two weeks after 
initiation. Both DMBA and TPA were dissolved in acetone (200 L/ one application). 
The number and size of tumors where monitored weekly. Mann-Whitney U and X2 
tests were run for statistical significance. 
 
Evaluation of Ki-67 staining in the mammary gland 
Mammary glands were stained for Ki67 and scanned using the Aperio slide scanner. 
A GENIE morphometry algorithm was created that identified ductal epithelial tissue 
in the glands and quantified the Ki67-positive nuclei within the epithelium. For each 
slide, an area of mammary gland was selected in which staining artifacts were 
minimal and no lymph nodes or other non-mammary tissue was present; the edges 
of the tissues were excluded from the area selected to eliminate problems caused 
by “edge effect”.  
 
Statistical analysis 
Where not specified, statistical analysis was performed using Student’s t-test.  
* indicates p <0.05; ** indicates p <0.01; *** indicates p <0.001. 
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Chapter 4 
 
The ER*-PRMT6 mouse model 
 
 
4.1 Characterization of tamoxifen-inducible ER*-PRMT6 chimera in cell lines 
The hormone-binding domain of steroid receptors can be used as a regulatory 
system to probe protein function (63). This approach has been used successfully to 
generate conditional forms of transcription factors (c-Myc, Stat3, p53), kinases (c-
Abl & Raf1), DNA methyltransferase (MGMT) and Cre recombinase (63,64). The 
development of a mutant estrogen receptor HBD (ER*) that is unable to bind 
estrogen, yet retains normal affinity for the synthetic ligand, tamoxifen (Tamox) or 4-
Hydroxytamoxifen (OHT), has enhanced this approach (65). Human PRMT6 was 
flag-tagged and fused to ER*, and then cloned into the pCAGGS expression vector 
(Figure 6A). In this system, ER*-PRMT6 expression is driven by the ubiquitous -
actin promoter (66). To test the approach, this expression vector was stably 
transfected into HEK 293 cells. In the absence of synthetic ligand, ER*-PRMT6 is 
localized to the cytoplasm, upon Tamox- or OHT-treatment the chimeric protein no 
longer interacts with the hsp90 complex, and is released for translocation into the 
nucleus where it is stabilized and active (Figure 6B).  This is indeed what we 
observed (Figure 6C). ER*-PRMT6 stable HEK 293 cells were fractionated into 
nuclear and cytoplasmic parts and subjected to WB  analysis using an Flag 
antibody. Prior to OHT-treatment, ER*-PRMT6 is restricted to the cytoplasmic 
fraction. After OHT-treatment, ER*-PRMT6 translocates to the nucleus and steadily 
accumulates there. Since PRMT6 is known to deposit the H3R2me2a mark (7-9), 
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we isolated core histones from the same cells used for the fractionation study in 
Figure 6C, and performed a WB analysis with an H3R2me2a antibody. Within two 
days, the H3R2 site becomes heavily modified (Figure 6D). 
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Figure 6. Characterization of an inducible ER*-PRMT6 fusion. (A) Human PRMT6 cDNA was cloned into the 
pCAGGS vector, downstream an ER* (a truncated version of the estrogen receptor that binds tamoxifen). A 
Flag-tag was introduced between the two proteins. The ubiquitous -actin promoter drives the expression of the 
chimeric ER*-PRMT6 protein. (B) Graphic depiction of this approach. ER*-PRMT6 is localized in the cytoplasm. 
Upon Tamox or OHT treatment the chimera protein becomes stabilized and translocates into the nucleus. C, 
HEK293 cells stably transfected with pCAGGS ER*-PRMT6 were treatment with OHT (2 M) and then 
separated into nuclear [N] and cytoplasmic [C] fractions. WB analysis was performed using an Flag antibody to 
detect ER*-PRMT6. An Lamin A/C WB was performed to confirm the quality of the nuclear/cytoplasmic 
fractionation. Time points after OHT-treatment are indicated. (D) Core histones were isolated from the same 
ER*-PRMT6 HEK 293 cells shown in (C). The core histones were subjected to WB analysis with an H3R2me2a 
antibody to monitor accumulation of this mark. Equal loading was confirmed by Ponceau staining and H3 WB 
analysis. 
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4.2 Characterization of tamoxifen-inducible ER*-PRMT6 transgenic mouse 
lines 
The pCAGGS-ER*-PRMT6 construct described above was used to generate three 
founder transgenic mouse lines – A, B & C (Figure 7A). Lines A and C underwent 
germ-line transmission, but Line C displayed low levels of transgene expression. 
Subsequent studies were thus focused on transgenic Line A. Tamox was 
administered to Line A mice by daily intra-peritoneal (IP) injections, for five days, as 
previously described (67). At this point, we analyzed the expression levels of the 
ER*-PRMT6 chimera in lysates generated from a number of organs (Figure 7B). In 
addition, immunohistochemical analysis of ER*-PRMT6 localization in the liver 
shows that IP administration of Tamox causes nuclear translocation and 
accumulation of this chimeric protein in the nucleus (Figure 7C). Apart from IP 
injection, Tamox can also be administered to the surface of the skin from where it is 
absorbed for the activation of ER* fusion proteins in the epidermis (68), but this 
delivery method also goes systemic. To determine whether ER*-PRMT6 could be 
induced with topical Tamox-treatment, Line A transgenic mice were shaved dorsally 
and painted with Tamox (1 mg) or vehicle (ethanol) daily for 5 days. We then 
performed immunofluorescence (IF) using the Flag antibody on paraffin-embedded 
skin sections and found that ER*-PRMT6 is strongly induced and localized to the 
nucleus of epidermal cells in these mice (Figure 7D). Epidermal scrapes were also 
collected from the Tamox-treated transgenic mice along with controls, and divided in 
equal amounts for tissue lysates and core histone extraction in order to perform 
PRMT6 and H3R2me2a WB analysis, respectively (Figure 7E). This experiment 
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revealed that topical Tamox-treatment of transgenic Line A mice results in a marked 
increase in H3R2me2a levels on the histone tail as a consequence of ER*-PRMT6 
stabilization in the epidermis. 
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Figure 7. The inducible ER*-PRMT6 fusion is functional in vivo. (A) Three transgenic lines were 
established using the pCAGGS ER*-PRMT6 vector. Southern analysis was performed with a PRMT6 
cDNA probe. The arrowhead indicates the transgene.  (B) IP injection of 1 mg Tamox, for five 
consecutive days, induced stabilization of ER*-PRMT6 in lung, brain and liver of Line A mice. The 
vehicle (sunflower oil) was injected as a control. (C) Immunohistochemistry (IHC) using an Flag 
antibody shows that upon IP injection of 1 mg Tamox (5 days) nuclear translocation of ER*-PRMT6 is 
induced in the liver of Line A mice. The vehicle (sunflower oil) was injected as a control. 
(D) Immunofluorescence for the Flag-tag performed on skin sections from transgenic Line A mice 
shows ER*-PRMT6 stabilization in the nucleus when Tamox was applied topically on shaved dorsal 
skin (1 mg/day) for 3 days. (E) Core histones were isolated from epidermal scrapes of topically 
Tamox-treated mice (1 mg every other day for 10 weeks) and subjected to WB with an H3R2me2a 
antibody. 
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4.3 ER*-PRMT6 mice: An unexpected phenotype  
Unexpectedly, ER*-PRMT6 transgenic mice that were subjected to daily topical 
Tamox treatment all died within a 3-week period (Figure 8A). Death occurred more 
rapidly (within 12 days) if Tamox (1 mg) was administered via IP injections (data not 
shown). Lethality could be avoided by applying Tamox (1 mg) topically every second 
day, although we did not observe a strong stabilization of the chimera in internal 
organs with this treatment (data not shown). In an effort to determine the cause of 
death of these mice, we performed several serum analyses, including evaluation of 
inflammatory cytokines such as Interleukin 6 (IL-6), Tumor Necrosis Factor alpha 
(TNF-alpha) and Interleukin 1 beta (IL-1), after topical application of Tamox (1 mg) 
for 12 consecutive days. IL-6 serum levels were significantly elevated in the 
transgenic Tamox-treated group (Figure 8B). The high variability observed in this 
assay may be due to the anti-inflammatory effects of tamoxifen, which has been 
shown to specifically interfere with NF-B activation (69-71). No significant 
difference in TNF-alpha or IL-1 was detected (data not shown). Since mouse 
keratinocytes are known to be a good source of IL-6 (72), we sought to confirm that 
ER*-PRMT6 stabilization increased IL-6 transcription in the Tg Line A primary 
keratinocytes. Therefore, we isolated these cells from newborn WT and Tg mice 
(Figure 8C), cultured for one day, treated with OHT for 2 days (without replacing the 
media), and stimulated with TNF-alpha 60 min prior to extracting RNA. As shown in 
Figure 8D, the keratinocytes derived from transgenic mice also show a significant 
increase in IL-6 transcription. 
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Figure 8. ER*-PRMT6 mice die upon stabilization of the chimera and show increased IL-6. (A) The ER*-
PRMT6 Line A mice die upon prolonged Tamox administration. A survival curve generated after topical Tamox 
administration (1 mg/day) until death of all transgenic mice occurred (n=14). WT mice were not impacted by this 
treatment. (B) IL-6 serum levels after 12 topical application of Tamox (1 mg/day) were measured by ELISA. IL-6 
serum levels (pg/mL) in four groups of animals (WT, WT Tamox treated, Tg Line A, Tg Line A Tamox-treated) are 
shown. Wilcox and Student t-tests were run and a p value of 0.004 was obtained for the Tg Tamox-treated group (n= 
32) when compared with the WT Tamox-treated group (n= 20) for both tests. All the mice in this study were healthy 
at the time of serum harvest. All mice were between 8 and 9 week-old, and females and males were equally 
represented. Primary keratinocytes isolation from 12 newborn mice (6 WTs and 6 Tgs) was performed (mice were 
from two litters). All cells were cultured for two days, treated with OHT (1M) for 48 hrs, and then treated with TNF-
alpha for 60 min, at which point and RNA isolation and cell lysates were performed. (C) WB for the flag tag on cell 
lysates shows stabilization of the ER*-PRMT6 in the Tg mice. A WB using keratin-5 antibody shows that these are 
indeed keratinocytes (as negative control we loaded a cytoplasmic extract of Line A MEFs). (D) RNA was analyzed 
by quantitative RT-PCR for the expression of IL-6 and normalized for GAPDH. The RQ difference between the two 
groups of mice is statistically significant (p = 0.0335). 
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4.4 PRMT6 interacts directly with the RelA subunit of NF-B 
The Nuclear Factor-kappa B is known to regulate the expression of inflammatory 
cytokines (28). PRMT family members CARM1 and PRMT1 have been shown to co-
activate NF-B-dependent gene expression (36,38). Thus, we asked if PRMT6 
might exhibit this function as well, which would explain the elevated levels of IL-6 
observed in the Line A transgenic mice. We first asked if PRMT6 is in the NF-B 
complex, by performing an immunoprecipitation (IP) using lysates of primary Mouse 
Embryonic Fibroblasts (MEFs) from WT and Tg Line A mice using an anti-Flag 
agarose. With this system we could co-IP endogenous RelA from the transgenic but 
not the WT cells (Figure 9A). In order to exclude the possibility that the ER* portion 
of the fusion protein could mediate this interaction, we transiently transfected HEK 
293 cells with constructs expressing GFP, GFP-CARM1 or GFP-PRMT6 along with 
a pCDNA-RelA vector for 48 hrs, then treated the cells with TNF-alpha for 30 min. 
IP using GFP or IgG antibodies was performed on cell lysates. WB using RelA 
antibody shows that RelA binds to GFP-CARM1 and GFP-PRMT6, but not to GFP 
alone (Figure 9C). CARM1 has previously been reported to interact with RelA, and 
it serves as a positive control in this experiment (36). A strong interaction was also 
confirmed by transiently transfecting a Flag-PRMT6 (not fused to ER*) construct in 
HEK 293 cells followed by co-IP experiments (Figure 9B). We were also able to co-
IP endogenous RelA by pulling down endogenous PRMT6 in HEK 293 cells (data 
not shown). 
The co-activators histone acetyltransferases p300 and its homolog, the 
CREB-1-Binding Protein (CBP) are known to impact NF-B-dependent gene 
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expression and have been shown to interact directly with RelA (31). Moreover, NF-
B-dependent gene expression involves another class of transcriptional 
coactivators, the steroid receptor-coactivators (SRCs), which interacts with the p50 
subunit of NF-B (32). PRMT6 has recently been shown to function as co-activator 
of several nuclear receptors (i.e. progesterone, glucocorticoid, and estrogen 
receptors) and to bind to SRC-1 in a mammalian two-hybrid assay (23). Therefore, 
we questioned if PRMT6 interacts directly with RelA or if the binding is bridged by 
other factors, such as SRC-1. For this purpose, GST and GST-RelA (1-431) were 
incubated with His-PRMT6, and a GST pull-down experiment was performed. After 
extensive washes, bound proteins were resolved on SDS-PAGE, followed by WB 
analysis using His antibody. As a negative control, a GST-Tudor domain (UHRF1) 
was incubated with His-PRMT6. As shown in Figure 9D, PRMT6 and RelA interact 
directly in this in vitro assay. 
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Figure 9. RelA co-immunoprecipitates with PRMT6 and they directly interact in vitro. (A) 
Primary MEFs were isolated from WT and ER*-PRMT6 Line A mice, cultured for 7 days and treated 
with OHT (2 M) for 24 hrs. Cells were then lysed and an immunoprecipitation (IP) was performed 
using Flag agarose. A WB  using RelA antibody reveals an interaction between the ER*-PRMT6 
and the endogenous RelA in the lysate from the transgenic cells. (B) HEK 293 cells were transiently 
co-transfected with a pCDNA-RelA vector and a pCAGGS-Flag-PRMT6 construct for 48 hrs, then 
treated with TNF-alpha for 30 min. IP using Flag agarose was performed on the cell lysates. A WB  
using RelA antibody shows that RelA is pulled down from the cells transfected with Flag-PRMT6, 
but not from the Mock (cells transfected with pCDNA-RelA vector and empty pCAGGS vector). (C) 
HEK 293 cells were transiently co-transfected with a pcDNA-RelA vector and constructs expressing 
GFP, GFP-CARM1 or GFP-PRMT6 for 48 hrs, then treated with TNF-alpha for 30 min. 
Immunopreciptation using GFP or IgG antibodies was performed on the cell lysates. A WB using 
RelA antibody shows that RelA binds to GFP-CARM1 and GFP-PRMT6, but not to GFP alone. (D) 
Direct binding between PRMT6 and RelA. GST and GST-RelA (1-431) were incubated with His-
PRMT6 and a GST pull-down was performed. For an additional negative control, GST-RelA was 
also incubated with a His-Tudor-UHRF1. A Western blotting using His antibody reveals direct 
binding between GST-RelA and His-PRMT6. 
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4.5 PRMT6 is a coactivator of NF-B and its enzymatic activity is required for 
this function  
In order to test if PRMT6 functions as a co-activator of NF-B, we first performed a 
luciferase assay using HEK 293 cells. PRMT6 overexpression increases the 
luciferase activity of a NFB-Luc luciferase reporter plasmid (Figure 10A). We used 
CARM1, a known co-activator for NF-B (36), as positive control for this experiment. 
Furthermore, the enzymatic activity of PRMT6 is required for its co-activator function 
(Figure 10B). This was established by transfecting HEK 293 cells with catalytic 
active and inactive forms of PRMT6 (PRMT6 dead), and performing a NFB-Luc 
luciferase assay. The inactive form of PRMT6 (VLD-KLA) has previously been used 
in a similar assay (14).  
To further confirm that PRMT6 functions as a coactivator of NFB, we 
performed quantitative real-time PCR experiments, in which we asked if, by 
overexpressing PRMT6 in HeLa cells, the transcription of IL-6 increases upon TNF-
alpha stimulation. We transfected HeLa cells with constructs expressing GFP, GFP-
PRMT6 or GFP-CARM1 (as positive control), and we observed enhanced 
transcription of IL-6 when either PRMT6 or CARM1 were overexpressed (Figure 
10C). We also explored the expression levels of several other genes known to be 
activated in HeLa cells upon TNF-alpha stimulation. These included TNF-alpha, 
Monocyte chemotactic protein 1 (MCP-1/CCL-2), Cyclooxygenase 2 (COX-2) and 
IkB-alpha (73). Among these genes, we found that PRMT6 co-activates TNF-alpha, 
MCP-1 and COX-2 (Figure 10C).  
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We then sought to understand if PRMT6 is essential for kB-dependent 
transactivation function. To this scope, we took advantage of PRMT6 KO MEFs 
availability in out laboratory (the PRMT6 KO mice were a gift from Dr. Stephane 
Richard) and performed Real-Time experiments with them. In this experiment, we 
treated WT, PRMT6 KO and CARM1 KO cells with TNF-alpha for 2 hrs and then 
extracted the RNA. As shown in Figure 10D, the PRMT6 and CARM1 cells display 
a significant reduced transactivation at the IL-6 locus compared to the WT cells. 
Therefore, although both PRMT6 and CARM1 enhance the transactivation of NF-kB 
at the IL-6 locus, neither of them is essential for this function.  These data are in 
agreement with the observations from the Hottiger’s group, who also did not see a 
defect in IL-6 activation in these CARM1 KO MEFs (36). 
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Figure 10. PRMT6 is a NF-B coactivator. (A) HEK 293 cells were transiently co-transfected with a NF-B firefly 
luciferase reporter plasmid and a renilla luciferase construct along with a GFP vector (Mock), a GFP-CARM1, or a 
GFP-PRMT6 construct. Cells were left un-stimulated or stimulated 20 hrs after transfection with TNF-alpha (10 ng/mL, 
6 hrs). Error bars represent standard deviation calculated from quadruplicate luciferase assays. Mean values are 
expressed as fold changes in luciferase activity with the un-stimulated Mock arbitrarily set as 1. The p values obtained 
for PRMT6 and CARM1 transfections compared to the Mock are 0.00016 and 0.0012, respectively, when a two sample 
independent t-test is run. These data are representative of four independent experiments. (B) HEK 293 cells were 
transiently co-transfected with a NF-B luciferase reporter plasmid and a renilla luciferase construct along with an 
empty vector or pMyc-PRMT6 or a PRMT6 catalytic inactive form (dead). Cells were un-stimulated or stimulated 20 hrs 
after transfection with TNF-alpha (10 ng/mL, 6 hrs). Error bars represent standard deviation calculated from 
quadruplicate luciferase assays. The p value obtained for the WT PRMT6 transfection is 0.0006, when a two sample 
independent t-test is run. (C) HeLa cells were transfected with GFP (Mock), GFP-PRMT6 or GFP-CARM1 constructs 
for 24 hrs and then stimulated with TNF-alpha (10 ng/mL) for 60 min. Total RNA was analyzed by quantitative RT-PCR 
for the expression of the indicated genes and normalized against GAPDH. For each gene, the TNF-alpha stimulated 
Mock group mean was arbitrarily set as 1. Error bars represent standard deviation calculated from triplicates. The 
asterisk indicates statistically significant difference compared to the Mock when a two sample independent t-test is run. 
For IL-6, the p values for GFP-PRMT6 and GFP-CARM1 versus Mock are 0.005 and 0.0004, respectively. For TNF-
alpha the p values for GFP-PRMT6 and GFP-CARM1 versus Mock are 9.2E-07 and 0.002 respectively. For MCP1 the 
p values for GFP-PRMT6 and GFP-CARM1 versus Mock are 0.3 and 0.07, respectively. For COX-2 the p values for 
GFP-PRMT6 and GFP-CARM1 versus Mock are 5.8E-05 and 0.64, respectively. (D) WT, PRMT6 KO and CARM1 KO 
MEFs were left untreated or stimulated with TNF-alpha for 2 hrs before RNA was extracted. Total RNA was analyzed 
by quantitative RT-PCR for the expression of IL-6 gene and normalized against GAPDH. The mean value for the 
unstimulated groups was arbitrarily set as 1. Error bars represent standard deviation calculated from triplicates. The 
asterisks indicate significant difference of these groups compared to the WT. The p values for TNF-alpha stimulated 
PRMT6 and CARM1 KO versus the WT cells are 0.0014 and 0.0038, respectively. 
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4.6 PRMT6 causes nuclear shuttling of RelA  
Having established that PRMT6 coactivates NF-B, we investigated the possible 
mechanism for this function. First, we explored the possibility that, when over-
expressed, PRMT6 may promote the movement of NF-B into the nucleus. For this 
purpose, we isolated primary MEFs from WT and ER*-PRMT6 embryos and treated 
them with OHT for 2 weeks. Cells were then fractionated and subjected to WB  
analysis using a RelA antibody. We observed an increase of nuclear RelA upon 
the Tamox-induced stabilization of ER*-PRMT6 in the nuclear fraction (Figure 11A). 
This effect on RelA nuclear shuttling was seen in MEFs isolated from additional 
embryos (data not shown). No change in global levels of RelA was observed in 
primary MEFs (Figure 11B). In order to confirm this phenomenon we performed IF 
in HeLa cells upon transient transfection with a GFP-PRMT6 construct. A GFP-
expressing construct was transfected in parallel for negative control. As shown in 
Figure 11C, cells overexpressing PRMT6 (which localizes strongly in the nucleus) 
show increased RelA in the nucleus. Thus, the overexpression of both GFP-PRMT6 
and ER*-PRMT6 causes increased nuclear RelA. This established that the ER* 
component of the ER*-PRMT6 fusion is not responsible for this translocation of 
RelA, but rather it is the PRMT6 protein itself.  
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Figure 11. PRMT6 promotes RelA shuttling into the nucleus (A) Primary MEFs were isolated from WT 
and ER*-PRMT6 mice, cultured for 3 days and treated with OHT for 2 weeks. Cell fractionation was 
performed. WB analysis for the Flag-tag shows stabilization of ER-PRMT6 in the nuclear fraction, 
corresponding to increased nuclear RelA. (B) Primary MEFs were isolated from 2 WT and 2 ER*-PRMT6 
mice, cultured for 3 days and treated with OHT for 3 days. Total cell lysates were analyzed by WB using 
RelA and Flag antibodies. Cells in which the ER*-PRMT6 is overexpressed do not show increased total 
levels of RelA.  (C) Immuno-fluorescence using a RelA antibody following transient transfection of GFP-
PRMT6 in HeLa cells shows increased nuclear RelA in transfected cells. A GFP-expressing construct was 
used as negative control.  
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4.7 A methylation-dependent mechanism for PRMT6 coactivator function 
The mechanism for PRMT6 co-activation is clearly methylation-dependent, as 
shown in Figure 10B. Posttranslational modification of RelA by PRMT6 could 
account for its increased nuclear localization. We thus tested the possibility that 
PRMT6 may methylate RelA by performing in vitro methylation assays. In this in 
vitro methylation assay, we observed robust methylation of histone H3, as well as 
automethylation of PRMT6 itself, but no methylation of recombinant RelA (Figure 12 
A,B). We then hypothesized that the coactivation is associated with the PRMT6 
action on the histone code. As mentioned above, PRMT6 has been shown to 
methylate the R3 position of the N-terminal tails of histones H4 in in-vitro reactions 
(9). Thus, we questioned if the ability of PRMT6 to function as a co-activator may be 
linked to its capacity to also methylate the R3 position of the N-terminal tails of 
histones H4 in vivo, generating the active H4R3me2a mark. To test this hypothesis, 
we utilized a specific H4R3me2a antibody and performed WB analysis on core 
histones isolated from primary MEFs of WT and Line A mice. As shown in Figure 
13A, ER*-PRMT6 Line A MEF core histones show a global increase in H4R3me2a 
when PRMT6 is stabilized in the nucleus by Tamox treatment for two weeks. To 
further confirm this, we transiently transfected HEK 293 cells with a pCAGGS-Flag-
PRMT6 construct and looked by WB. In this experiment, we saw a more dramatic 
global elevation of the H4R3me2a activating mark (Figure 13B). As PRMT1 is 
known to be the primary enzyme generating the H4R3me2a mark, we sought to test 
if PRMT6 could rescue this mark when PRMT1 is knocked out (KO). We took 
advantage of the availability of an OHT-inducible PRMT1 KO stable line, previously 
described (74), which we stably transfected with our ER*-PRMT6 construct. As 
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shown in Figure 13C, while the PRMT1 KO cells have a dramatic reduction in the 
H4R3me2a mark upon OHT treatment, the stable line we generated shows rescue 
of this mark upon concomitant loss of PRMT1 and overexpression of PRMT6 (ER*-
PRMT6), therefore PRMT6 is able to maintain the H4R3me2a modification in 
absence of PRMT1. 
We then asked if PRMT6, like CARM1 (36), might be recruited to the IL-6 
promoter upon TNF-alpha stimulation and if the H4R3me2a mark concomitantly 
increases at this locus, therefore we performed chromatin immunoprecipitation 
(ChIP) using PRMT6, H4R3me2a and H3R2me2a antibodies. We clearly observe 
enrichment of PRMT6 and H4R3me2a at the transcriptional start site (TSS) of IL-6 
upon TNF-alpha stimulation (Figure 14). These data strongly suggest that PRMT6 
is recruited to chromatin with RelA, where it impacts the histone code and/or 
possibly methylates other chromatin-associated proteins to facilitate transcription at 
the IL-6 locus. 
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Figure 12. PRMT6 does not methylate RelA in vitro. (A) GST-PRMT6 was incubated with 
recombinant histone H3, GST, or GST-RelA (1-431) and the methyl-donor tritiated S-adenosyl-
methyonine (SAM) for 30 min. The reactions were then resolved by SDS-PAGE and transferred to a 
PVDF membrane. A fluorography revealed strong activity of PRMT6 on recombinant histone H3, while 
no activity was detected on RelA (1-431). (B) Flag-PRMT6 was pulled down from HEK 293 cells upon 
TNF-alpha stimulation (10ug/mL, 30 min.) and incubated with histone H4 or GST-RelA (1-431).  
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Figure 13. PRMT6 generates the H4R3me2a active mark in vivo. A, Primary MEFs were isolated from 
WT and ER*-PRMT6 mice, cultured for 3 days and treated with OHT for 2 weeks.  Cell fractionation and 
core histone isolation was performed. A WB for Flag shows stabilization of the ER-PRMT6 in the nuclear 
fraction from the Tg OHT-treated cells. A WB on core histones shows increased H3R2me2a as well as 
H4R3me2a global levels in the Tg OHT-treated cells. B, HEK 293 cells were transiently transfected with a 
pCAGGS-Flag-PRMT6 vector or an empty vector (Mock) and a WB for PRMT6 showed a highly efficient 
expression of the exogenous flag-PRMT6 compared to the endogenous, while PRMT1 levels were 
unchanged. A WB for Actin was used for loading control. Core histones from these cells were extracted and 
subjected to WB using H4R3me2a and H3R2me2a antibodies, which revealed an increase of these 
marks in the cells over-expressing Flag-PRMT6, while H4R3me2s or H3K4me3 levels did not change. C, An 
OHT-inducible PRMT1 knockout MEF line (PRMT1FL/- ;ER-Cre), previously described, was stably transfected 
with our ER-PRMT6 construct. Cells were left untreated or treated with 2M OHT along with the MEF 
inducible PRMT1 knock-out cells and a MEF control line (PRMT1+/+ ;ER-Cre) for 7 consecutive days. WB for 
PRMT1 and PRMT6 on cell lysates were performed. A WB for beta-Actin is shown for loading control. Core 
histones from the cells were extracted and a WB for H4R3me2a was performed. A WB for Histone H4 
showed equal histone loading. 
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Figure 14. PRMT6 ChIPs at the TSS of IL-6, with concomitant increase in the H4R3me2a 
mark upon TNF-alpha stimulation. HeLa cells were transiently transfected with a Flag-PRMT6 
construct, and a ChIP assay was performed using Flag, H3R2me2a and H4R3me2a 
antibodies. Upon TNF-alpha stimulation (60 min), PRMT6 is enriched at the transcriptional start 
site (TSS), corresponding to the consensus region for NF-kB.  The H3R2me2a repressive mark 
is unchanged, while the H4R3me2a active mark is significantly enriched. 
Error bars represent standard deviation calculated from triplicates. Mean values are fold 
changes compared to the IgG and normalized to a control intergenic region about 8000bp 
upstream the TSS. The asterisk indicates statistically significant difference compared to the un-
stimulated when a two sample independent t-test is run.  
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Chapter 5 
The Cre-inducible mouse model 
 
5.1 The Cre-inducible system  
A Cre-inducible hPRMT6 transgene was cloned using the pCAGGS vector, which 
harbors a beta-actin promoter. Between the promoter and PRMT6 we placed a Stop 
cassette, which is flanked by directly repeated loxP sites (Figure 15A). This Stop 
cassette terminates transcripts, as previously described (62), and is excised by the 
action of a Cre recombinase. The excision capability of a Cre recombinase was first 
tested in vitro, by transforming the stop-cassette containing vector in a Cre-
expressing E. coli strain. With this system, the linearized construct isolated from this 
strain is shorter than the linearized construct used to transform the cells, due to the 
stop-cassette excision, therefore a gel shift of about 1,400bp (the stop cassette 
length) can be appreciated (Figure 15B).  
Before attempting to generate mice, the inducible expression of the Flag-
PRMT6 was also tested in cultured cells by performing WB analyses with an Flag 
antibody upon co-transfection of HEK 293 cells with the pCAGGS-stop-PRMT6 
construct and a GFP-Cre expressing vector (Figure 15C). For positive control (last 
lane on the right) we transfected cells with the construct isolated from Cre-
expressing E. coli (Figure 15B, lane 2), which, as expected, gives a very efficient 
expression of the Flag-PRMT6. To ascertain that the stop cassette was efficient in 
blocking transcription, we also transfected cells with the pCAGGS-stop-PRMT6 
construct, which, as expected, does not express Flag-PRMT6.  
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Figure 15. PRMT6 is re-expressed from a pCAGGS-stop-PRMT6 construct upon Cre 
recombination. (A) Depiction of the Cre-inducible PRMT6 construct. A Flag-hPRMT6 cDNA was cloned 
into the pCAGGS vector, downstream a loxP- eta-actin promoter 
drives the expression of the Flag-PRMT6 transgene. Upon Cre recombination, the stop cassette is 
excised and a loxp-Flag-PRMT6 is left. (B). The system was tested for Cre recombination by using a 
Cre-expressing E. coli strain. In lane 1 is the pCAGGS-stop-PRMT6 linearized construct, while in lane 2 
is the same construct after transformation and isolation from the Cre-expressing E. coli. A gel shift is 
indicative of proper excision of the stop cassette.  (C) HEK 293 cells were transfected with an empty 
pCAGGS vector (Mock) or a pCAGGS-stop-PRMT6 construct along with a GFP-Cre vector, or a 
pCAGGS-stop-PRMT6 construct or a pCAGGS-loxp-PRMT6 construct. After 24 hrs, cells were 
harvested and a WB for Flag was performed on the cell lysates.  
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5.2 Ex vivo characterization of Cre-inducible mouse lines  
The construct described above was employed to generate transgenic mouse lines, 
which we call STOP-PRMT6 mice. From a first pronuclear injection we obtained 2 
lines (Line 1 and 2) (Figure 16A, left), but neither line re-expressed the transgene 
upon Cre recombination. From a second pronuclear injection we obtained three 
additional lines (Line 3, 4, 5) (Figure 16A, right), all of which showed re-expression 
of the transgene upon Cre recombination. To test the re-expression of Flag-PRMT6 
we isolated primary MEFs from these mouse lines, transfected them with a GFP-Cre 
vector, and tested the expression of the transgene by WB using a specific anti-
hPRMT6 antibody. As seen in Figure 16B, Line 1 and 2 do not re-express 
exogenous PRMT6 upon Cre recombination, while Line 3, 4, 5 re-express the Flag-
PRMT6. The double band present in all the lanes is a non-specific doublet 
recognized by the specific anti-hPRMT6 antibody in use. To further confirm 
expression of Flag-PRMT6 we also performed IF analyses on all the lines using 
anti-Flag antibody. For Line 1 and 2 we did not see re-expression of Flag-PRMT6 
(data not shown), while for Line 3, 4, 5 we confirmed the re-expression  (Figure 
16C). In this IF, the green nuclei (which are the ones transfected with GFP-Cre) are 
indeed positive for Flag staining (in purple).   
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Figure 16. Characterization of STOP-PRMT6 MEFs.  (A) Five transgenic lines were established using the 
pCAGGS-stop-PRMT6 vector. Southern analysis was performed with a PRMT6 cDNA probe. The arrowhead 
indicates the transgene.  (B) Primary MEFs were isolated from Line 3, 4 and 5 and cultured for 7 days, then an 
electroporation using a pCAGGS-GFP-Cre vector was performed. Cells were harvested 24 hrs later and a WB using 
a specific anti-hPRMT6 antibody was performed. The double band that appears under the specific human PRMT6 
and s present in the negative control cells is an a-specific band. (C) An aliquot of primary MEFs from the 
electroporation described in  (B) was plated on coverslip and an IF using anti-Flag antibody was performed.  
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5.3 Crossing the STOP-PRMT6 lines with K5-Cre mice 
We crossed Line 3, 4 and 5 to keratin 5 (K5)-Cre transgenic mice (75). The K5-Cre 
mouse line was chosen because PRMT6 is overexpressed in a number of epithelial 
cancers (lung, breast, cervical and bladder cancer – Figure 5E), where the K5 
promoter is active. This line is on a FVB background and was available in Science 
Park from Dr. David Johnson’s laboratory. When crossed with K5-Cre, all three lines 
generated bigenic pups that were slightly smaller than their single transgene (or 
WT) littermates and displayed a delay in hair development (Figure 17A), although 
these differences were not appreciable once the mice reached adulthood. At 
histological level, a hair follicle phenotype was observed. Indeed, hair follicle were 
somewhat disorganized, with the appearance of transversally oriented hair follicles 
which embedded in the fat layer (Figure 17B, arrowhead). The bigenic mice of Line 
4 displayed the most severe phenotype at both gross and histological levels. 
Epidermal scrapes were performed on the skin from the bigenic mice of the three 
lines, and these lysates were subjected to WB analysis using anti-hPRMT6 
antibody, which revealed expression of the exogenous form of PRMT6 in all the 
lines (Figure 18A). Although the expression of Flag-PRMT6 seemed to be good in 
WB analyses, IF analyses revealed a very focal expression in both epidermis and 
hair follicles in all the lines. In Figure 18B is shown the IF for the Flag-tag on 
paraffin embedded skin sections of STOP-PRMT6/K5-Cre (Line 4)  mice.  
Since STOP-PRMT6 bigenic mice of Line 4 harbor the least transgene copy 
number (Figure 16A), show the strongest Flag-PRMT6 expression in the epidermis 
and the most obvious hair follicle phenotype (Figure 17), we decided to focus on 
this line for further characterization and experiments. We will refer to the Line 4 as 
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STOP-PRMT6 from here on. In addition to the epidermis, the K5-Cre transgene is 
also expressed in a number of other stratified and pseudo-stratified epithelial 
tissues, including the cervix, vagina, oral and nasal cavities, esophagus, stomach, 
bladder, lung, thymic epithelial, prostate, and myoepithelial cells of the mammary 
gland (76), therefore we performed a WB analysis on lysates from several organs of 
the STOP-PRMT6/ k5-Cre bigenic mice using a antih-PRMT6 antibody. As seen in 
Figure 19A, the expression of exogenous PRMT6 is predominant in epidermis, 
mammary gland and thymus. A residual expression was seen in brain and liver. 
Next, we analyzed the core histones isolated from STOP-PRMT6/K5-Cre epidermal 
scrapes. We observed a clear elevation of H3R2me2a levels in the bigenic mice 
(Figure 19B) by WB. Finally, we performed double immuno-fluorescent staining 
using anti-H3R2me2a (green) and anti-Flag (red) antibodies on paraffin-embedded 
sections from the skin of STOP-PRMT6/K5-Cre bigenic mice. We observed a 
dramatic elevation of H3R2me2a levels in cells expressing Flag-PRMT6 (Figure 
19C). These data show that the Tg4 line has an altered histone code and provides 
in vivo evidence for PRMT6 impacting epigenetic signatures. 
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Figure 17. Bigenic mice of the K5-Cre cross display a hair phenotype. (A) Pups of each STOP-
PRMT6 line that we obtained (Line 3, 4, 5) display delayed hair onset upon Cre recombination. (B) H&E 
sections of 3-week-old STOP-PRMT6/ K5-Cre mice showing the hair follicle phenotype.   
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Figure 18. The expression of Flag-PRMT6 is extremely focal in the skin of bigenic mice. (A) 
Epidermal scrapes were collected from bigenic mice of the three lines of the STOP-PRMT6 mice 
that we generated and subjected to WB analyses using a specific anti-hPRMT6 antibody. (B) Skin 
sections from bigenic STOP-PRMT6/K5-Cre (Line 4) mice were paraffin embedded and subjected to 
IF staining using anti-Flag antibody.  
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Figure 19. STOP-PRMT6/ K5-Cre mice display elevated H3R2me2a mark. (A) Organ lysates from 
a STOP-PRMT6 /K5-Cre mouse were subjected to WB analyses using a specific anti-hPRMT6 
antibody. (B) Epidermal scrapes from a bigenic and a control mouse were collected and divided in two 
parts to perform WB analyses for PRMT6 and H3R2me2a on lysates and core histones, respectively.  
(C) Sections from skin of bigenic mice were paraffin embedded and a co-IF was performed using 
mouse anti-Flag (red) and rabbit anti-H3R2me2a (green) antibodies. 
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5.4 A chemical skin carcinogenesis study on STOP-PRMT6/K5-Cre mice 
Having observed a gross skin phenotype in live K5-Cre/STOP-PRMT6 bigenic mice 
and demonstrated overexpression of PRMT6 and increased levels of the PRMT6-
mediated H3R2me2a mark in bigenic epidermis, we hypothesized that pathological 
effects of PRMT6 overexpression in the epidermis and possibly other K5-expressing 
tissues may be detectable. The gross skin phenotype that is observed in our bigenic 
lines, including the alopecia, is similar to the phenotype observed for a number of 
other K5 transgenic models that have hyperplastic and hyperproliferative epidemis, 
including K5 models that overexpress Myc (77) and E2F1 (78). These models also 
develop spontaneous tumors in the skin and other K5-expressing tissues. Moreover, 
deregulated expression of Myc in the epidermis of transgenic mice resulted in an 
enhanced response to two-stage skin carcinogenesis (77). We hypothesized that 
STOP-PRMT6/K5-Cre bigenic mice may have increased susceptibility to skin 
carcinogenesis as well.  This is consistent with the strong correlative data 
demonstrating that PRMT6 is overexpressed in several different human cancers. In 
order to test our hypothesis we carried out a two-stage DMBA/TPA skin 
carcinogenesis study on STOP-PRMT6/K5-Cre mice. Mice were initiated by 
applying 25μg DMBA once and promotion was performed applying 5μg TPA/week 
twice a week for 23 weeks, following the protocol from the group of Yuspa (79). As 
control group the K5-Cre mice were included in this study. We compared a number 
of endpoints, including tumor incidence, burden, multiplicity, and malignancy. A two 
group Chisq test with a 0.050 two-sided significance level will have 80% power to 
detect the difference between a Group 1 proportion of 0.3 and a Group 2 proportion 
of 0.7 when the sample size in each group is 25. Therefore, we included 27 bigenic 
 64 
mice  in this study. When we examined papilloma incidence, number, and burden 
we did not observe significant difference between the STOP-PRMT6/K5-Cre bigenic 
group and the control group (Figure 20). When we examined the number of 
squamous cell carcinomas (SCC) and spindle cell carcinomas (SCT) we also did not 
detect significant difference between the two groups. However, spindle cell 
carcinomas, which are believed to represent a more advanced form of SCC, were 
absent in the control group while 5 total were detected in the bigenic group.  
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Figure 20. Results of the chemical skin carcinogenesis study. (A) Papilloma incidence during the 23-week 
TPA treatment. Tumors were counted every second week. (B) Tumor burden (cumulative for all the mice), 
expressed in cm. (C) Tumor multiplicity, expressed in number of papillomas/mouse. (D) Analysis of the 
malignancies at the endpoint of the carcinogenesis study (mice were sacrificed at 23 weeks of TPA 
administration). MiSCC, Microinvasive Squamous Cell Carcinomas: SCC, Squamous Cell Carcinomas; SCT, 
Spindle Cell Carcinomas.  
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5.5 A cancer study on STOP-PRMT6/K5-Cre;p53+/- mice to investigate the role 
of PRMT6 in tumorigenesis 
The p53+/- mice exhibit a wide array of tumors, including soft tissue sarcomas, 
osteosarcomas and carcinomas of various types starting at about 9 months of age 
(80). In order to determine if increased PRMT6 activity cooperates with p53 
deficiency in tumor development we generated STOP-PRMT6/K5-Cre;p53+/- mice. 
These mice were all 100% FVB. The breeding scheme to generate these mice is 
shown in Figure 21. As shown in Figure 19A, the expression of the exogenous 
hPRMT6 is quite extensive in the bigenic STOP-PRMT6/K5-Cre mice, therefore the 
impact of PRMT6 overexpression on tissue homeostasis and malignancy could be 
examined in a variety of organs using this model system.  Importantly, PRMT6 
overexpression is observed in tumors from several of the tissues that are targeted 
by the K5 transgene, including the cervix, bladder, lung and breast (Figure 5E). In 
performing this cancer study, we hypothesized that increased PRMT6 expression 
and activity would cooperate with p53 inactivation to accelerate tumor development, 
and we were especially interested in potential effects of PRMT6 overexpression on 
mammary tumor development. We calculated that 20 double transgenic mice should 
be enough to detect a statistically significant difference between the control and the 
experimental groups. [If PRMT6 over-expression increases tumor incidence to 80% 
by one year, then 20 mice per group will be enough to detect a statistically 
significant difference in tumor incidence (a two group chi-square test with a 0.05 one 
sided significance level will have 80% power to detect the difference between 40% 
and 80% when the sample size is each group is 18)]. We obtained total of 34 
bigenic mice (females and males were equally represented in the group) and 
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monitored them for tumor formation over 10-month period along with the K5-Cre 
control group (Table 1). Complete necropsy was performed by Dr. Donna Kusewitt 
and any lesion or abnormal looking organ was taken for histopathological analysis 
when mice were about 9 months old. It has to be noted that we experienced a loss 
of about 25-30% of mice from each group during the time period of this study (Table 
1). Deaths were sudden and started around 5 months of age. We did not investigate 
on the cause of deaths, especially considering that this was a phenomenon 
happening for all the groups. Mice that died before the endpoint of this study were 
therefore discarded. Overall, in this study there was not a significant difference in 
tumorigenicity between the two groups, but the bigenic mice showed signs of 
increased inflammation. 
Consistent with our findings about PRMT6 role in inflammatory response 
described in Chapter 4, overall there appeared to be increased inflammation 
(perivasculitis in the lung and kidney and microabscess in the liver) in the STOP-
PRMT6/K5-Cre females compared to the K5-Cre control females (Figure 22, 
arrowheads) although the difference was not statistically significant, probably due to 
the inadequate number of females left at necropsy.  This phenomenon was not seen 
in the males. 
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 Figure 21. Breeding scheme to generate STOP-PRMT6/K5-Cre;p53+/- mice. 
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Figure 22. STOP-PRMT6/K5-Cre females from the tumor study (p53+/- cross) display 
perivasculitis in the lungs and microabscess in the liver. Representative H&E staining of liver and 
lungs of K5-Cre control and STOP-PRMT6/K5-Cre bigenic females. Arrowheads indicate 
microabscess and perivasculitis.  (Pictures taken by Dr. Donna Kusewitt). 
 
Table 1.  Control and transgenic mice employed in the cancer susceptibility study. 
 
 70 
5.6 Crossing the STOP-PRMT6 mice with a MMTV-Cre mouse line 
Transgenic mouse lines carrying a Cre recombinase under the control of the MMTV 
LTR (MMTV-Cre, Line A and Line D) have been generated by the group of 
Hennighausen (81,82). We crossed our transgenic STOP-PRMT6 with the MMTV-
Cre Line D, which was available in Science Park from Dr. Marcelo Aldaz’ group. 
This strain originated on an FVB background, but has been backcrossed to 
B6129F1 and is now only available in this background from the Jackson’s 
repository. MMTV-Cre Line D mice display high levels of recombination in the virgin 
and lactating mammary gland, salivary gland, seminal vesicle, skin, erythrocytes, B 
cells and T cells when crossed to ROSA26-lox-Stop-lox-LacZ reporter strain, while 
little background recombination is observed in the lung, kidney, liver and brain 
tissues (less than 10%) (81). In crossing STOP-PRMT6 mice with MMTV-Cre mice 
we kept the background at 50% FVB component. 
We first sought to compare the expression level of the exogenous PRMT6 in 
the bigenic STOP-PRMT6/MMTV-Cre mice versus the bigenic STOP-PRMT6/ K5-
Cre mice, therefore we harvested mammary gland tissue and performed WB 
analyses using anti-hPRMT6 antibody - which revealed an equal level of expression 
in these two crosses (Figure 23A) - as well as immunohistochemistry (IHC) staining 
on paraffin embedded tissue using anti-Flag antibody (Figure 23B). The IHC shows 
extensive (although mosaic) expression of the exogenous PRMT6 in mice from both 
crosses, but there seems to be a difference in the compartment of cells that express 
the exogenous Flag-PRMT6: the K5-Cre cross appears to be mostly luminal, while 
the MMTV-Cre cross appears to be both myoepithelial and luminal. In order to 
evaluate the level of over-expression of the exogenous PRMT6 in comparison to the 
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endogenous protein and the histone arginine methylation status in the epithelial 
compartment of the mammary gland, we isolated primary mammary epithelial cells 
(organoids) from the bigenic STOP-PRMT6/MMTV-Cre mice along with the controls 
(single transgenic STOP-PRMT6 mice). As shown in Figure 24A, WB analysis on 
the cell lysates using an anti-PRMT6 antibody (which recognizes human and mouse 
PRMT6) reveals a strong over-expression of the exogenous Flag-PRMT6 compared 
to the endogenous protein. WB analyses were performed on core histones isolated 
from these cells to investigate levels of asymmetric dimethylation on H3R2 as well 
as H4R3. As shown in Figure 24A the global H3R2me2a and H4R3me2a (although 
to a lesser extent) levels are elevated in the mammary gland epithelium from the 
double transgenic mice compared to the single transgenic controls. We then took 
advantage of the mosaic expression displayed by the Tgs STOP-PRMT6/MMTV-
Cre mice to perform double immuno-fluorescence for the Flag-tag and the histone 
marks of our interest. The epithelial mammary gland cells from the double 
transgenic mice that do not express the exogenous Flag-PRMT6 (red) display lower 
H3R2me2a and H4R3me2a, shown in green (Figure 24B). Therefore, we were able 
to confirm that PRMT6 methylates the H4R3 site in vivo with these mice. 
Since PRMT6 impacts epigenetic signatures in vivo in our mouse model, we 
questioned if PRMT6 may induce increased proliferation in the mammary gland of 
the bigenic mice. For this evaluation (done by Dr. Donna Kusewitt) we examined the 
proliferative marker Ki-67, as described in the Materials and Methods Chapter.  For 
STOP-PRMT6/K5-Cre mice, we utilized the females from the tumor study described 
in Section 5.5, but we did not detect any difference between the K5-Cre control 
group and the bigenic STOP-PRMT6/K5-Cre group (data not shown), however we 
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did see a difference in Ki-67 staining for the bigenic STOP-PRMT6/ MMTV-Cre mice 
compared to the control groups (WT, STOP-PRMT6, and MMTV-Cre)  (Figure 
25A). We also examined the percentage of the area that was composed by ducts in 
the four groups. Interestingly, the percentage of the area examined that was 
composed of ducts in the MMTV-Cre mice was higher, although not statistically 
significant, than the WT and STOP-PRMT6. The percentage of the area occupied 
by ducts was higher in the bigenic mice compared to control groups MMTV-Cre, WT 
and STOP-PRMT6, although the p value was significant only when the comparison 
was done with the WT and STOP-PRMT6 groups (Figure 25B). In more simple 
terms we can summarize these data by stating that the MMTV-Cre mice per se 
display more epithelialization than WT mice, but the overexpression of PRMT6 in 
these mice seems to increase this phenotype.  
Having ascertained a hyper-proliferative phenotype in the mammary gland of 
the bigenic STOP-PRMT6/MMTV-Cre mice, we set-up an ageing study to 
investigate the possibility of increased spontaneous mammary carcinogenesis in 
these mice compared to the controls. These mice have been aged until 12 months 
and analyses on the mammary tissue are currently underway.  Some of the bigenic 
mice have developed large mammary tumors, which are being examined by our 
pathologist.  
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Figure 23. Flag-PRMT6 expression analysis in the mammary gland of bigenic STOP-PRMT6/MMTV-
Cre mice. (A) STOP-PRMT6 mice were crossed with a K5-Cre mouse line and a MMTV-Cre mouse line. 
WB analysis on the mammary gland extracts using an anti-hPRMT6 antibody shows expression of the 
exogenous PRMT6 in the bigenic females from each cross. (B) Immuno-histochemistry using an anti-Flag 
antibody on paraffin embedded mammary gland tissue is shown here. 
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Figure 24. Bigenic STOP-PRMT6/MMTV-Cre mice display elevated histone arginine 
methylation in the mammary gland epithelium. Primary mammary epithelial cells were isolated 
from bigenic STOP-PRMT6/ MMTV-Cre and control (single transgenic) females and cultured for 3 
days. (A) Cell lysates were subjected to WB analysis using an aPRMT6 antibody which recognizes 
human and mouse PRMT6. Core histones were isolated and subjected to WB analysis using 
H3R2me2a and H4R3me2a specific antibodies. (B) Double immuno-fluorescence using 
Flag/H3R2me2a or Flag/H4R3me2a antibody combinations was also performed.  
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Figure 25. STOP-PRMT6 /MMTV-Cre female mice display increased proliferation in the mammary 
gland.  The fourth mammary glands from 13-14 week-old females were paraffin-embedded and stained for 
the proliferative marker Ki-67. The groups of mice under evaluation were WT (n=7), MMTV-Cre (n=6), 
STOP-PRMT6 (n=7) and bigenic STOP-PRMT6/MMTV-Cre (n=7).  (A) Evaluation of number of Ki-67 
positive nuclei per mm2 duct tissue. The p value is 0.015 when the bigenic group is compared to the MMTV-
Cre group. (B) Percentage of the selected area that was identified as being occupied by ducts. For statistical 
analysis, the Student t test was used. Values are for a 2-tailed t-test assuming unequal variance. p values 
are 0.014, 0.046 and 0.38 when the bigenic group is compared to the WT, STOP-PRMT6 and MMTV-Cre 
group, respectively. 
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5.7 A RNA-Seq experiment to investigate the impact of PRMT6 overexpression 
on mammary gland transcriptome 
Since two regulatory histone marks, namely H3R2me2a and H4R3me2a, are 
aberrantly methylated in the mammary gland of the bigenic STOP-PRMT6/ MMTV-
Cre mice, we sought to investigate the impact of PRMT6 over-expression on the 
transcriptome by performing a RNA-Seq experiment in this system. In order to 
perform this experiment, we isolated organoids from the bigenic STOP-
PRMT6/MMTV-Cre, along with 2 control groups  (STOP-PRMT6 and MMTV-Cre). 
After 3 days in culture, we isolated the RNA from these cells and carried out the 
RNA-SEq experiment (done by the Molecular Biology core of Science Park). In this 
experiment, by applying the EdgeR analysis, we found a list of 127 differentially 
regulated genes (mostly repressed in the bigenic mammary cells). With a more 
stringent analysis (DESeq) the list of genes differentially regulated consists of 17 
genes (Table 2), which have yet to be confirmed by qPCR. This experiment 
suggests that PRMT6 indeed has a significant impact on gene expression. 
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Gene 
 
Fold difference between bigenic and 
control  
(log2ratio)   (fold difference) 
 
p value 
Fxyd6 
 
     (-1.50402426)    (0.352568561) 
 
3.70E-06 
 
Anpep 
 
(-1.149596896)  (0.450751158) 
 
3.58E-05 
 
Serpine2 
 
 (-0.875114644) (0.545210539) 
 
6.77E-06 
 
Ucp2 
 
 (-0.867534022) (0.548082881) 
 
6.06E-06 
 
Mgst1 
 
 (-0.814857227) (0.568464741) 2.97E-05 
 
Adamts3 
 
(-0.813866665) (0.568855186) 
 
1.98E-05 
 
4931406C07Rik 
 
(-0.807541437)  (0.571354701) 
 
5.96E-07 
 
 Add3 
 
(-0.688727492)  (0.620400824) 
 
2.01E-05 
 
Prom1 
 
(-0.678246736)  (0.624924265) 
 
8.21E-07 
 
Mansc1 
 
(-0.652710633)  (0.636084073) 
 
6.20E-06 
 
Cdon 
 
(-0.641127291)   (0.641211724) 
 
4.68E-05 
 
Man1c1 
 
   (-0.62168415)    (0.649911801) 
 
4.67E-05 
 
Tmem176a 
 
(-0.610811553)  (0.654828241) 
 
4.58E-05 
 
Sort1 
 
   (-0.593026224)  (0.66295083) 
 
3.18E-05 
 
Lama3 
 
   (0.86487064)     (1.821176374) 4.88E-05 
 
Abcc4 
 
   (0.886930746)  (1.849237784) 
 
5.41E-05 
 
Nup210l 
 
   (1.058591443)  (2.08289692) 
 
 
3.61E-05 
 
Table 2. List of genes differentially regulated in the mammary gland epithelial compartment of bigenic 
STOP-PRMT6/MMTV-Cre mice. RNA was isolated from primary mammary epithelial cells of STOP-
PRMT6/MMTV-Cre, STOP-PRMT6 and MMTV-Cre mice. An RNA-Seq experiment was carried out and data were 
analyzed by DESeq. In red are the repressed genes, in green the up-regulated genes when the bigenic group was 
compared to the MMTV-Cre group. Data were reproducible when the bigenic group was compared to the STOP-
PRMT6 group. 
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Chapter 6 
Discussion and Future Directions 
 
In this thesis I describe gain-of-function PRMT6 mouse models, which, to our knowledge, 
are the first PRMT6 transgenic models to be generated.  The phenotype of the mouse 
model with ubiquitous PRMT6 stabilization (the ER*-PRMT6 model) is complex, with 
activated PRMT6 likely impacting the methylation levels of many substrates. The 
impacted substrates include dramatic changes in the histone code (which we have 
observed), and possibly elevated methylation levels on non-histone substrates.  
Chromatin is an active platform that mediates external and internal cellular signals into 
dynamic changes in gene expression. Studies on high-order complexes during activation 
of NF- -regulated genes and the consequent impact on chromatin remodeling through 
histone post-translational modification (PTM) have increased enormously in the past 
decade and it has become clear that the NF-B transactivation is far more complex than 
anticipated (26). A number of coactivators and mediators have been discovered to 
regulate its transcriptional activity, indeed NF-B recruits a coactivator complex that has 
striking similarities to that recruited by steroid nuclear receptors and the role of factors that 
impact histone tail posttranslational modifications has become evident (31). Histone 
arginine methylation by protein arginine methyltransferases has elicited a great deal of 
interest due to increasing evidence that it regulates chromatin remodeling and gene 
expression by providing docking sites for specific readers or effector molecules (4,24,83).  
Herein I have shown that PRMT6 functions as a coactivator for NF-B-mediated gene 
transcriptional activity. I arrived at this finding by observing an activated inflammatory 
response in the transgenic ER*-PRMT6 mice. The specific involvement of PRMT6 in up-
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regulating inflammatory genes was confirmed by demonstrating that overexpression of 
PRMT6 enhances NF-B transcriptional activity in cultured cell-based luciferase assays 
and quantitative real-time PCR experiments. The activity of PRMT6 was clearly necessary 
for the coactivator function. ChIP analysis demonstrated that PRMT6 was recruited to the 
IL-6 promoter upon TNF-alpha stimulation. Moreover, overexpression of PRMT6 caused 
RelA shuttling into the nucleus, which could justify, at least in part, the mechanism 
underlying its coactivator function. Notably, PRMT6 has been found overexpressed in 
many types of human cancers (39,55,56), therefore the facilitation of NF-B nuclear 
shuttling could be an important mechanism contributing to NF-B-dependent gene 
activation in cancer (84). It remains to be addressed if the increased nuclear RelA is the 
result a direct shuttling due to PRMT6 binding to it or an indirect consequence of PRMT6 
overexpression. Moreover, the increased PRMT6 localization at the IL-6 promoter upon 
stimulation is indicative of regulatory signaling on PRMT6, possibly by post-translational 
modification. One question that I sought to answer is: what is the role of arginine 
methylation in PRMT6 coactivation of NF-B transcription? A number of PTMs on NF-B 
subunits have been shown to affect its stability, function, subcellular localization and 
binding to DNA (85). It has recently been published that PRMT5 (a type-II arginine 
methyltransferase) methylates p65/RelA (86). This methylation event appears to increase 
the ability of NF-B to bind to B elements and to drive gene expression. I investigated 
the possibility of PRMT6 methylating RelA using in vitro methylation assays, but found 
that this is not the case. Other modes of PRMT6 regulation could be through the 
methylation of non-histone proteins that are associated with the NF-B complex or 
through its ability to methylate histones. A recent publication has shown that PRMT6 
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behaves like PRMT1 and CARM1, indeed it works as a secondary coactivator to 
p160/SRC proteins (23). PRMT6 binds to the AD2 domain of SRC-1, and synergistically 
coactivates ERα together with SRC-1. Therefore, PRMT6 can be considered a steroid 
hormone receptor coactivator which interacts with SRC-1 to facilitate transcription. A likely 
mechanism by which PRMT6 will function as a coactivator has recently come to light with 
the finding that it methylates a site in the core of histone H3, H3R42me2a (25). 
Importantly, the side chain of this arginine residue interacts with the DNA minor groove 
and methylation of this site is proposed to sterically interfere with this interaction, as well 
as remove a potential hydrogen bond donor, thus destabilizing the histone:DNA 
interaction. Indeed, the incorporation of semisynthetic H3R42me2a into core histone 
octamers, and use of these octamers in reconstituted chromatin for the generation of 
chromatinized transcription template revealed this to be the case. Unfortunately, there are 
currently no antibodies available to the H3R42me2a mark, so we are unable to test the 
hypothesis that this histone methylation site is responsible for the coactivator functions of 
PRMT6 in the context of nuclear receptor and NF-B signaling. PRMT6 has also been 
reported to generate the active site H4R3me2a in vitro (9), therefore I sought to 
investigate if this mark is also generated in vivo, which could account for a mechanism of 
coactivation. I found that indeed not only PRMT6 overexpression causes global increase 
of this mark in vivo, but also that this mark enriches at the IL-6 promoter upon TNF-alpha 
stimulation in ChIP assays, concomitantly with PRMT6 recruitment, although the influence 
of PRMT1 in this assays cannot be excluded. The impact of PRMT6 on H4R3 could also 
explain the coactivator function towards nuclear receptors, but this hypothesis remains to 
be tested. 
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Due to lethality of the ER*-PRMT6 mouse model, I could not carry out cancer 
studies with it, therefore a Cre-inducible mouse model was generated, allowing for tissue-
specific overexpression of PRMT6. These mice were crossed to K5-Cre and MMTV-Cre 
mice. The first experiment I set up was a skin carcinogenesis study utilizing the bigenic 
STOP-PRMT6/K5-Cre mice, but did not observe a difference in tumorigenicity between 
the experimental and control groups. This is likely due to the extreme focal nature of the 
Flag-PRMT6 expression in the epidermis and hair follicles of the bigenic mice. According 
to the cancer stem cells hypothesis for cancer development, the mechanism for tumor 
initiation in two-stage carcinogenesis protocols that employ DMBA/TPA involves mutation 
in the critical target Ha-ras gene of stem cells in the bulge region of hair follicles or basal 
compartment of interfollicular epidermis (57). It is thus likely that none of the cells that 
were targeted for Ha-ras mutation by the initiating agent DMBA was in fact over-
expressing the exogenous Flag-PRMT6, therefore no difference in tumor susceptibility 
was detected.  
From the second cancer study I carried out (by performing a cross with p53+/- 
mice) I did not detect increase tumorigenicity in the bigenic STOP-PRMT6/K5-Cre;p53+/- 
mice compared to the controls, although an interesting phenomenon occurred, indeed the 
females of the bigenic group showed signs of ongoing inflammatory response. This result 
is in line with our observations of the ER*-PRMT6 model, which also showed an 
inflammatory response upon PRMT6 stabilization. One question that arises is: why do 
only the females showed this phenotype? Although there are numerous reports showing 
negative cross-talk between ER and NF-B (70,87-90), these transcription factors have 
also been shown to act synergistically (91-95) by forming a complex at the estrogen 
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responsive elements (EREs) or NF-B responsive elements found in gene promoters.  In 
particular, the group of Stanculescu (95) has shown that E2 enhances TNF- alpha activity 
on ≈15 % of TNF-alpha up-regulated genes. With this in mind, I can speculate that the 
increased inflammatory response observed in the female mice in our study might be the 
result of this synergism, given that PRMT6 is a coactivator for both these transcription 
factors. 
With the MMTV-Cre cross I found an interesting phenotype, indeed the bigenic 
STOP-PRMT6/MMTV-Cre mice displayed a hyper-proliferative phenotype in the 
mammary gland, which was detected by Ki-67 analysis (see Figure 25). Upon this 
observation, I set-up an ageing study to investigate the possibility of increased 
spontaneous mammary carcinogenesis in the bigenic STOP-PRMT6/ MMTV-Cre mice 
compared to the controls. It is possible that the MMTV-Cre transgene per se is creating 
the ideal conditions for PRMT6 to enhance cancer susceptibility. Peculiar phenotypes in 
Cre-expressing mouse lines have been previously described. For example one of the 
MMTV-Cre lines (the Line A) that were generated by the group of Hennighausen (82) 
displays a lactation defect (96). For this reason, this line has been cryopreserved and is 
not currently being used by any laboratory. The mice from the MMTV-Cre cross have 
been aged until 12 months and analyses on the mammary tissue along with the controls 
are underway.  Some of the bigenic mice have developed large mammary tumors that are 
currently being examined. If this study turns out to be inconclusive, it might be worth to 
cross the STOP-PRMT6 mice with an oncogenic mouse model (i.e. MMTV-Myc mouse), 
considering the hypothesis that PRMT6 may have a role in tumor promotion rather than 
initiation. In the future, this type of mouse model could be valuable for the in vivo analysis 
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of small molecule PRMT inhibitors that are currently being developed both in academic 
and pharma sets (97). 
From the last experiment I carried out (RNA-Seq on primary mammary epithelial 
cells) we found a list of genes that are potentially - directly or indirectly- regulated by 
PRMT6. One gene that is up-regulated is miR-1943. MicroRNAs (miRNAs) have shown to 
play important roles in physiological and malignant processes, including acute myeloid 
leukemia (AML). The group of Humphries (98) applied the Illumina massively parallel 
sequencing platform to carry out an in-depth analysis of the miRNA transcriptome in a 
murine leukemia progression model and found miR-1943 among the most significantly up-
regulated miRs.  It would be interesting to investigate if there is direct regulation of this 
miR by PRMT6 at chromatin level, since PRMT6 is up-regulated in leukemia. 
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